University of Kentucky

UKnowledge
Neuroscience Faculty Patents

Neuroscience

3-7-2017

Amidated Dopamine Neuron Stimulating Peptides for CNS
Dopaminergic Upregulation
Luke H. Bradley
University of Kentucky, lhbradley@uky.edu

Don M. Gash
University of Kentucky, dongash@email.uky.edu

Greg A. Gerhardt
University of Kentucky, gregg@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/neurobio_patents
Part of the Medical Anatomy Commons, and the Medical Neurobiology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Bradley, Luke H.; Gash, Don M.; and Gerhardt, Greg A., "Amidated Dopamine Neuron Stimulating Peptides
for CNS Dopaminergic Upregulation" (2017). Neuroscience Faculty Patents. 10.
https://uknowledge.uky.edu/neurobio_patents/10

This Patent is brought to you for free and open access by the Neuroscience at UKnowledge. It has been accepted
for inclusion in Neuroscience Faculty Patents by an authorized administrator of UKnowledge. For more information,
please contact UKnowledge@lsv.uky.edu.

Illlll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
US009586992B2

c12)

United States Patent

(10)

Bradley et al.

(45)

(54)

AMIDATED DOPAMINE NEURON
STIMULATING PEPTIDES FOR CNS
DOPAMINERGIC UPREGULATION

(71)

Applicant: University of Kentucky Research
Foundation, Lexington, KY (US)

(72)

Inventors: Luke Bradley, Lexington, KY (US);
Don Marshall Gash, Lexington, KY
(US); Greg Gerhardt, Nicholasville,
KY (US)

(73)

Assignee: University of Kentucky Research
Foundation, Lexington, KY (US)

( *)

Notice:

(21)

Appl. No.: 14/153,844

(22)

Filed:

(65)

Subject to any disclaimer, the term ofthis
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

Jan. 13, 2014
Prior Publication Data

US 2014/0148393 Al

May 29, 2014

Related U.S. Application Data

(60)

Division of application No. 12/646,511, filed on Dec.
23, 2009, now abandoned, which is a
continuation-in-part of application No. 12/508,916,
filed on Jul. 24, 2009, now abandoned, which is a
continuation-in-part of application No. 12/447,213,
filed as application No. PCT/US2007/022696 on Oct.
26, 2007, now abandoned.

(60)

Provisional application No. 60/854,693, filed on Oct.
27, 2006, provisional application No. 61/140,365,
filed on Dec. 23, 2008.

(51)

Int. Cl.
C07K 7106
(2006.01)
(2006.01)
A61K 38108
(2006.01)
A61K 38110
(2006.01)
C07K 7108
U.S. Cl.
CPC ................ C07K 7106 (2013.01); A61K 38108
(2013.01); A61K 38110 (2013.01); C07K 7108
(2013.01)
Field of Classification Search
None
See application file for complete search history.

(52)

(58)

(56)

References Cited

FOREIGN PATENT DOCUMENTS
WO

WO 2005/023861

3/2005

OTHER PUBLICATIONS
Chen et al. "Transgenic Mouse Models of Dopamine Deficiency"
Ann Neurol 2003;54 (suppl 6):S91-Sl02.*

Patent No.:
US 9,586,992 B2
Date of Patent:
Mar. 7, 2017

Shah et al. "Current approaches in the treatment of Alzheimer's
disease" Biomedicine & Pharmacotherapy 62 (2008) 199-207.*
Sato et al., Synthesis and Circular Dichroism Studies of
Oligopeptides Having Tri- or Tetra-L-Prolyl Sequences, Bull.
Chem. Soc. Jpn. 1984, 57: 1679-1680.
Fukui et al., Studies of bitter peptides from casein hydrolyzate. I.
Synthesis of bitter peptide BPia corresponding to Arg-Gly-Pro-ProPhe-Lle-Val from casein hydrolyzate by alkaline proteinase of
Bacilus subtilis, Bull. Chem. Seo. Jpn. 1983, 56: 766-769.
Kundu, Synthesis, Conformational Features and Biological Activity
of [Pro3] Antiarrhythmic Peptide, Collect. Czech. Chem. Commun.
1989 54: 760-771.
Kawasaki et al., Amino acids and peptides. XVI. Synthesis of
N-terminal tetrapeptide analogs of fibrin .alpha.-chain and their
inhibitory effects on fibrinogen/thrombin clotting, Chem. Pharm.
Bull. 1992, 40: 3253-3260.
Sofou et al., Synthesis of a proline-rich [60]fullerene peptide with
potential biological activity, Tetrahedron 2004, 60: 2823-2828.
Striplin et al., Solvent Dependence of Intramolecular Electron
Transfer in a Helical Oligoproline Assembly, J. Am. Chem Soc.
2004, 126: 5282-5291.
T. Immonen etla., A proGDNF-related peptide BEP increases synaptic excitation in rat hippocampus, ScienceDirect, Experimental
Neurology 210 2008, pp. 793-796.
Nutt JG, et al. (2003) Randomized, double-blind trial of glial cell
line-derived neurotrophic factor (GDNF) in Pd. Neurology. Jan. 14,
2003;60( 1):69-73.
Lang AE, et al. (2006) Randomized controlled trial of
intraputamenal glial cell line-derived neurotrophic factor infusion in
Parkinson disease. Ann Neurol. Mar. 2006;59(3):459-66.
Lo Bianco C, et al. (2004) Lentiviral nigral delivery of GDNF does
not prevent neurodegeneration in a genetic rat model of Parkinson's
disease. Neurobiology of Disease 17: 283-289.
Marks Jr. et al., (2010) Gene delivery of AAV2-neurturin for
Parkinson's disease: a double-blind, randomised, controlled trial.
Lancet Neurology. 2010; 9: 1164-72.
Decressac M, et al. (2011) GDNF fails to exert neuroprotection in
a rat a-synuclein model of Parkinson's disease. Brain 134(8):
2302-2311.
Cullen KM, Halliday GM, Double KL, Brooks WS, Creasey H,
Broe GA. Cell loss in the nucleus basalis is related to regional
cortical atrophy in Alzheimer's disease. Neuroscience 1997; 78 (3)
641-52.
Lyness SA, Zarow C, Chui HC. Neuron loss in key cholinergic and
aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol
Aging. 2003;24(1): 1-23.
Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR.
Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10(2):122-6.
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon
MR. Alzheimer's disease and senile dementia: loss of neurons in the
basal forebrain. Science. 1982;215(4537):1237-9.

* cited by examiner
Primary Examiner - Christina Bradley
(74) Attorney, Agent, or Firm - Crowell & Moring LLP

(57)

ABSTRACT

The present invention relates to novel proteins, referred to
herein as amidated glial cell line-derived neurotrophic factor
(GDNF) peptides (or "Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)"), that are useful for treating brain diseases and injuries that result in dopaminergic
deficiencies.
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Human Glial-eell 'Derived Neurotrophic Factor Precursor1 isotype 1 (GDNF}
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AMIDATED DOPAMINE NEURON
STIMULATING PEPTIDES FOR CNS
DOPAMINERGIC UPREGULATION

229 (2004)). Neurotrophic factors are also capable of promoting the re-growth of damaged neurons and their processes both in vitro and in animal models (see Lad, S. P. et
al., "Individual and combined effects of TrkA and p75NTR
nerve growth factor receptors: A role for the high affinity
receptor site", J Biol Chem 278: 24808-24817 (2003a) and
Lad, S. P. et al., "Nerve growth factor: structure, function
and therapeutic implications for Alzheimer's disease", Curr
Drug Targets CNS Neural Disord 2: 315-334 (2003b)).
Identifying neurotrophic factors with the right combination
of protective and restorative actions and developing effective strategies for drug delivery have profound therapeutic
implications for Parkinson's disease, Alzheimer's disease,
Huntington's disease and other degenerative processes in the
brain (including those induced by brain injury).
Glial cell line-derived neurotrophic factor (GDNF) is a
trophic factor shown to dramatically protect and enhance the
function of dopamine neurons in vitro and in vivo in rodents
and monkeys (Beck, K. D., et al., "Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced
degeneration in the adult brain", Nature, 373:339-41
(1995); and Bjorklund, A., et al., "Towards a neuroprotective
gene therapy for Parkinson's disease: use of adenovirus,
AAV and lentivirus vectors for gene transfer of GDNF to the
nigrostriatal system in the rat Parkinson model", Brain
Res., 886:82-98 (2000), Gash, D. M., et al., "Functional
Recovery in Parkinsonian Monkeys Treated with GDNF,
Nature", 380:252-255 (1996); Grondin, R., et al., "Striatal
GDNF Infusion Promotes Structural and Functional Recovery in Advanced Parkinsonian Monkeys. Brain", 125:21912201 (2002); Grondin, R., et al., "GDNF Increases Stimulusevoked Dopamine Release and Motor Speed in Aged Rhesus
Monkeys", J. Neurosci., 23:1974-1980 (2003); Hebert M.
A., et al., "Functional Effects of GDNF in Normal Rat
Striatum: Presynaptic Studies Using In Vivo Electrochemistry and Microdialysis", J. Pharm. Exp. Ther., 279:11811190 (1996); Hebert M.A. and Gerhardt, G. A., "Behavioral
and Neurochemical Effects of Intranigral GDNF Administration on Aged Fischer 344 Rats", J. Pharm. Exp. Ther.,
282: 760-768 (1997); Hou, J. G. G., et al., "Glial Cell
line-Derived Neurotrophic Factor Exerts Neurotrophic
Effects on Dopaminergic Neurons In Vitro and Promotes
Their Survival And Regrowth After Damage by l-Methyl-4Phenylpyridinium ", J. Neurochem., 66: 74-82 (1996); Kordower, J. H., et al., "Clinicopathological Findings Following Intraventricular Glial-Derived Neurotrophic Factor
Treatment in a Patient with Parkinson's Disease", Ann
Neural., 46(3):419-424 (1999); Kordower, J. H., et al.,
"Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease",
Science, 290: 767-773 (2000); Palfi, S., et al., "Lentivirally
Delivered Glial Cell Line-derived Neurotrophic Factor
Increases the Number of Striatal Dopaminergic Neurons in
Primate Models of Nigrostriatal Degeneration", J. Neurosci., 22:4942-4954 (2002); Tomac, A., et al., "Protection and
Repair of the Nigrostriatal Dopaminergic System by GDNF
In Vivo", Nature, 373:335-339 (1995)).
The current standard treatment, levodopa, is palliative and
does not prevent the relentless progression of Parkinson's
degeneration. GDNF exerts effects on dopamine neurons
that slow the process of Parkinson's disease and even
reverses some of the degenerative changes. Preclinical studies conducted to date suggest that GDNF exerts at least three
general trophic actions on dopamine neurons in the substantia nigra: pharmacological upregulation, restoration and
neuroprotection. With regard to pharmacological upregulation, GDNF upregulates dopaminergic functions, such as
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FIELD OF THE INVENTION
The present invention relates to novel proteins, referred to
herein as amidated glial cell line-derived neurotrophic factor
(GDNF) peptides (or "Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)"), that are useful for treating brain diseases and injuries that result in dopaminergic
deficiencies.
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Neurotrophic factors are endogenous proteins that modulate cell signaling pathways regulating stem cell proliferation, neuronal differentiation, differentiation, growth and
regeneration (Barde Y, "Trophic factors and neuronal survival", Neuron 2:1525-1534 (1989); Gatz, R., et al., "The
conservation of neurotrophic factors during vertebrate evolution", Comp Biochem Physiol Pharmacol Toxicol Endocrinol 108: 1-10 (1994); and Goldman, S. A., "Adult neurogenesis: from canaries to the clinic", J Neurobiol 36:
267-86 (1998)). They are generally small, soluble proteins
with molecular weights between 13 and 24 KDa and often
function as homodimers. Because of this physiological role,
neurotrophic factors are useful in treating the degeneration
of nerve cells and the loss of differentiated function that
occurs in a variety of neurodegenerative diseases.
Many neurotrophic factors are both neuroprotective (protecting neurons from injury) and neurorestorative (promoting structural and functional regeneration). The best defined
protective functions are seen during neural development.
During development, excessive numbers of neurons are
generated in many brain regions. Developing neurons that
fail to make connections with appropriate trophic factor
producing target cells are deprived of necessary neurotrophic factors and die. Those neurons that establish connections survive and function properly (e.g. NGF; see
Campenot, R. B. and Maclnnis, B. L. "Retrograde transport
of neurotrophins: fact and function", J Neurobiol 58: 217-
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increasing the evoked release of dopamine (Gerhardt, G. A.
et al., "GDNF improves dopamine function in the substantia
nigra but not the putamen of unilateral MPTP-lesioned
rhesus monkeys", Brain Res 817: 163-171 (1999) and Grondin et al., 2003). It also appears to modulate the phosphorylation of TH (Salvatore, M. et al. "Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in
the rat striatum and substantia nigra". J Neurochem. 90:24554, (2004)). With regard to restoration, GDNF increases the
number of neurons expressing the dopamine markers TH
and DAT in the substantia nigra (Gash et al., 1996; Kordower et al., 2000; and Grondin et al., 2002). This suggests
that one trophic action is to stimulate recovery of injured/
quiescent nigral neurons. Supporting this interpretation is
the consistent observation that GDNF promotes increases in
dopamine neuron perikaryal size and the number of neurites.
With regard to neuroprotection, nigrostriatal administration
of GDNF either shortly before or following a neurotoxic
challenge (e.g. 6-0HDA, methyl-amphetamine or MPTP)
protects dopamine neurons from injury in rodents and nonhuman primates (Kordower et al., 2000 and Fox, C. M.,
"Neuroprotective effects of GDNF against 6-0HDA in
young and aged rats", Brain Res 896:56-63 (2001)).
Accordingly, GDNF therapy is expected to be helpful in
the treatment of nerve damage caused by conditions that
compromise the survival and/or proper function of one or
more types of nerve cells. Such nerve damage may occur
from a wide variety of different causes. Nerve damage may
occur to one or more types of nerve cells by, for example: (1)
physical injury, which causes the degeneration of the axonal
processes and/or nerve cell bodies near the site of injury; (2)
temporary or permanent cessation of blood flow to parts of
the nervous system, as in stroke; (3) intentional or accidental
exposure to neurotoxins, such as chemotherapeutic agents
(e.g., cisplatinum) for the treatment of cancer or dideoxycytidine (ddC) for the treatment of AIDS; (4) chronic
metabolic diseases, such as diabetes or renal dysfunction; or
(5) neurodegenerative diseases such as Parkinson's disease,
Alzheimer's disease, and Amyotrophic Lateral Sclerosis
(ALS), which result from the degeneration of specific neuronal populations.
GDNF therapy may be particularly helpful in the treatment of neurodegenerative conditions involving the degeneration of the dopaminergic neurons of the substantia nigra,
such as Parkinson's disease. The expected impact ofGDNF
therapy is not just to produce an increase in the dopaminergic neurotransmission at the dopaminergic nerve terminals
in the striatum (which will result in a relief of the symptoms), but also to slow down, or even stop, the progression
of the degenerative processes and to repair the damaged
nigrostriatal pathway and restore its function. GDNF may
also be used in treating other forms of damage to or
improper function of dopaminergic nerve cells in human
subjects. Such damage or malfunction may occur in schizophrenia and other forms of psychosis. The only current
treatments for such conditions are symptomatic and require
drugs which act upon dopamine receptors or dopamine
uptake sites, consistent with the view that the improper
functioning of the dopaminergic neurons which innervate
these receptor-bearing neuronal populations may be
involved in the disease process.
However, initial clinical trials involving ventricular delivery of GDNF showed no statistically significant differentiation of the placebo and active treatment groups (Nutt, J. G.
et al. "Randomized, double-blind trial of glial cell linederived neurotrophic factor (GDNF) in PD", Neurology 60:
69-73 (2003)), perhaps because insufficient amounts of

GDNF reached critical target sites from the CSF (Ai, Y. et
al., "Intraputamenal Infusion in Aging Rhesus Monkeys:
Distribution and Dopaminergic Effects", J Comp Neural
461: 250-26125 (2003); and Kordower, J. H., et al. (2000)).
In addition, a phase 2 trial evaluating intraputamenal delivery of glial cell line-derived neurotrophic factor (GDNF) for
the treatment of Parkinson's disease failed to achieve its
primary end point, a 25% improvement on the Unified
Parkinson Disease Rating Scale (UPDRS) motor score "off'
medication after six months of treatment (Lang, A. E. et al.,
"Randomized controlled trial of intraputamenal glial cell
line-derived neurotrophic factor infusion in Parkinson's
disease", Ann Neural 59:459-466 (2006)). There are strong
indications from studies in rhesus monkeys using the same
delivery system and protocol followed in the phase 2 study
that drug bioavailability significantly contributed to the
failure of the trial (Salvatore et al., "Point source concentration of GDNF may explain failure of phase II clinical
trial". Exp Neural 202 (2): 497-505 (2006)). The concentration of GDNF around the catheter tip and limited diffusion
into surrounding brain parenchyma was limited to a brain
volume representing 2-9% of the human putamen. Thus
GDNF distribution in the phase 2 trial was likely limited to
a small brain region, and could affect only a limited segment
of the brain undergoing parkinsonian degeneration.
Successful trophic factor therapy requires site-specific
delivery and distribution of the trophic factor throughout the
target tissue (the putamen for Parkinson's disease). The
blood brain barrier effectively blocks entry from blood borne
proteins, including trophic factors. Infusions into the cerebrospinal fluid are not effective in humans because of brain
size and may produce unwanted side effects by stimulating
other trophic factor responsive populations such as sensory
neurons.
In addition to focal delivery into the appropriate site, the
delivery must be tightly regulated. Regardless of the method
used to deliver GDNF (i.e., direct infusion, stem cells,
encapsulated cells, gene therapy) prolonged elevated levels
of GDNF in the brain outside of the target area may produce
adverse side-effects. Circulating antibodies to GDNF are
one possible outcome and it is quite typical to find antibodies
to endogenous proteins used therapeutically (e.g. beta interferon and insulin, see Durelli, L., et al., "Anti-interferon
antibodies in multiple sclerosis: molecular basis and their
impact on clinical efficacy", Front Biosci 9: 2192-2204
(2004) and Stoever, J. A. et al., "Inhaled insulin and insulin
antibodies: a new twist to an old debate", Diabetes Technol
Ther 4: 157-161 (2002)). The effects of circulating GDNF
antibodies are not known. Focal Purkinje cell lesions have
been reported in some monkeys receiving high levels of
GDNF in a toxicology study (see Sherer, T. B., et al.,
Movement Dis 21:136-141 (2006)). Another possible sideeffect is aberrant sprouting and tyrosine hydroxylase downregulation of the nigrostriatal dopaminergic pathway in rats
exposed to high GDNF levels from viral vector gene transfer
(Georgievska, B., et al. "Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a
lentiviral vector", Neuroreport 13: 75-82 (2002)). Also,
increased neuronal death has been reported in rats with
elevated GDNF from viral vector gene transfer in a stroke
model (Arvidsson, A. et al., "Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats", Neurobiol Dis 14: 542-556,
(2003)).
While GDNF has not met the criteria for clinical efficacy
in the two phase 2 trials conducted to date (Nutt et al., 2003;
Lang et al., 2006), it appears to be the most potent dop-
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aminergic trophic factor found to date. Thus, the ideal drug
for treating Parkinson's disease and other neurodegenerative
processes in the brain would possess the positive trophic
actions of GDNF. Delivery could be targeted to the appropriate brain area by any of a number of methods including
direct infusion, viral vectors or even nasal sprays. In particular, biologically active peptides with trophic actions may
offer many of the desired properties. To date, such biologically active peptides have not been identified.
A crude peptide extract from the brain cerebrolysin has
been tested in human studies, with modest effects reported
(Lukhanina, E. P. et al., "Effect of cerebrolysin on the
electroencephalographic indices of brain activity in Parkinson's disease", Zh Nevrol Psikhiatr Im SS Korsakova 104:
54-60 (2004)). Three small molecule compounds have also
been tested in Parkinson's disease patients: the tripeptide
glutathione, tocopherol, and Coenzyme QlO (Weber, C. A.,
et al. "Antioxidants, supplements and Parkinson's disease",
Ann Pharmacother 40: 935-938 (2006)). The three small
molecule compounds also appear to have only minor benefits for patients.
Consequently, there continues to exist a long-felt need for
effective agents and methods for the treatment and prevention of brain diseases and injuries that result in dopaminergic
deficiencies. Accordingly, it is an object of the present
invention to provide agents for treating and preventing such
diseases and injuries in a subject, comprising novel amidated GDNF-derived peptides that have dopaminergic
trophic factor activity. This and other such objectives will be
readily apparent to the skilled artisan from this disclosure.

FIG. 4 depicts the average K+-evoked release of dopamine in Fischer 344 rats treated with ADNS peptides.
FIG. 5 depicts the increase in major metabolites of
dopamine in Fischer 344 rats treated with ADNS peptides.
FIG. 6 depicts the increased survival of dopamine neurons
in cell cultures treated with ADNS peptides.
FIGS. 7A and B depict the results of in vivo microdialysis
used to investigate the dynamics of dopamine release in the
basal ganglia of the right putamen following treatment with
ADNS peptides.
FIGS. SA-F depict the histopathological response to the
injection of ADNS peptides in the nigral region using
standard histochemical techniques.
FIGS. 9A-D depict a series of photomicrographs evaluating the substantia nigra compacta (SNc) containing the
population of dopamine neurons that degenerates in Parkinson's disease after treatment with ADNS peptides.
FIGS. lOA and B depict the sequence origin and homology of dopamine neuron stimulating peptide-11 (DNSP-11 ).
FIGS. llA-D depict the neurotropic effects of DNSP-11
and GDNF on mesencephalic (A and B) and MN9D (C and
D) dopaminergic cells.
FIGS. 12A-C depict the effects ofDNSP-11 in normal (A)
and unilateral 6-0HDA-lesioned (B and C) rats.
FIG. 13 depicts the interactions of DNSP-11 with protein
partners.
FIG. 14 depicts the gel filtration analysis of the interaction
between GAPDH and GDNF.
FIGS. 15A-C depict the solubility and stability ofDNSP11 at various storage and experimental conditions.
FIG. 16 shows the effects of citrate vehicle or DNSP-11
on resting levels of DOPAC one month after a single
infusion.
FIG. 17 shows the broad distribution of DNSP-11 in the
rat substantia nigra region of the midbran within 30 minutes
of DNSP-11 injection (panels A-F).
FIG. 18 shows the DNSP-11 increased State III oxygen
consumption vs. vehicle in both the SN and striatum, 28
days post bilateral intrnigral injections (*p<0.05 vs control,
two-tailed, unpaired tests). (A) Substantia nigra 28 days; (B)
Striatum 28 days.
FIG. 19 demonstrates that DNSP-11 produced a significant, about 50%, decrease in apomorphine-induced rotational behavior (A) and significantly increased levels of
dopamine and the dopamine metabolite, DOPAC, by about
100% in the substantia nigra (B).
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SUMMARY OF THE INVENTION
In one embodiment, the present invention provides a
composition comprising at least one of the following peptides: (a) a purifiedAmidated Dopamine Neuron Stimulating
peptide (ADNS peptide) comprising the amino acid
sequence ERNRQAAAANPENSRGK-amide (SEQ ID NO:
2); (b) a purified ADNS peptide comprising the amino acid
sequence FPLPA-amide (SEQ ID NO: 3); and (c) a purified
ADNS peptide comprising the amino acid sequence PPEAPAEDRSL-amide (SEQ ID NO: 4). In another embodiment,
the present invention provides a method for treating a brain
disease or injury resulting in dopaminergic deficiencies,
comprising administering a pharmaceutically effective
amount of the composition to a subject in need thereof,
wherein said composition further comprises at least one of
a pharmaceutically acceptable vehicle, excipient, and
diluent. Preferably, the subject is a mammal, and most
preferably, the subject is human.
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BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 depicts the nucleotide sequence (top strand) and
amino acid sequence (bottom strand) of mature human
GDNF (SEQ ID NO: 5 and SEQ ID NO: 1).
FIG. 2 depicts the post-translational processing of splice
form 1 of human GDNF. Sequences from top to bottom are:
SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO:
9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ
ID NO: 13, SEQ ID NO: 3, SEQ ID N0:4, and SEQ ID NO:
2.
FIG. 3 depicts the precursor segments of the ADNS
peptides ERNRQAAAANPENSRGK-amide (SEQ ID NO:
2), FPLPA-amide (SEQ ID N0:3), and PPEAPAEDRSLamide (SEQ ID N0:4). From top to bottom SEQ ID NO: 8,
SEQ ID NO: 14, and SEQ ID N0:15.
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DETAILED DESCRIPTION OF THE
INVENTION
Human glial cell line-derived neurotrophic factor
(hGDNF) is synthesized as a precursor that is processed and
secreted as a mature protein of 134 amino acids. Mature
human GDNF has the amino acid sequence depicted in FIG.
1 (SEQ ID NO: 1).
The present invention is related to the realization that
human GDNF (splice form 1) precursor protein conforms to
a rather exacting sequence profile characteristic of neuropeptide precursor proteins. GDNF is expressed in at least
three isoforms that result from alternative splicing of
mRNA. Proteins expressed from these RNA splice variants
differ in their N-terminal regions (see NCBI entry NP
000505 for isoform 1; NCBI entry NP 964701 for isoform
2; and NCBI entry NP 954704 for isoform 3). Isoforms 1 and
2 are secretory protein precursors with N-terminal signal
peptides. Isoform 3 is likely a nuclear-targeted protein with
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a nuclear localization signal (NLS), but no signal peptide.
The three isoforms are differentially expressed, apparently
under regulatory control.
All of the isoforms contain the sequence that is considered
mature GDNF with "full biological activity" (residues
78-211 in isoform 1). In fact, recombinant proteins further
truncated at the N-terminus are purported to have the "full
biological activity". From the fact that three separate precursors of the same GDNF molecule are expressed under
separate regulation, two with signal peptides and the third
with a probable nuclear localization signal, suggests that
there are both nuclear and cell surface receptors for GDNF.
The separately regulated expression of two different
secretory isoforms (isoforms 1 and 2) suggests a biologically
significant function for the different N-terminal sequences of
the isoforms. The conventional wisdom is that residues
20-77 of isoform 1 precursor constitute a "domain propeptide". The present invention provides a new interpretation of
the importance of the 20-77 "domain propeptide" region of
isoform 1 precursor. The "domain propeptide" segment of
isoform 1 precursor is the metabolic precursor of two small
amidated peptides, according to well established enzymatic
pathways for release of peptide amide hormones and neuropeptides from their precursor proteins. The two small
amidated peptides are FPLPA-amide (SEQ ID NO: 3) and
PPEAPAEDRSL-amide (SEQ ID NO: 4).
Furthermore, a third small amidated peptide, ERNRQAAAANPENSRGK-amide (SEQ ID NO: 2), may be
released from consensus enzymatic processing of residues
88-110 of the isoform 1 precursor. This consensus peptide
amide precursor occupies the N-terminal sequence of
"mature GDNF", which is presumably not critical or at least
includes residues that are not critical for biological activity,
according to the patent literature. The isoform 2 precursor
contains the sequence FPLPA (SEQ ID NO: 16), but does
not contain the amidation signal (GKR, residues 25-27) in
the case of Isoform 1 precursor. Isoform 2 is not, in other
words, a potential precursor ofFPLPA-amide (SEQ ID NO:
3) according to known enzymatic pathways. Isoform 3 does
not contain the sequence FPLPA at all, so likewise can not
be a metabolic precursor ofFPLPA-amide (SEQ ID NO: 3).
Both Isoforms 1 and 2 are consensus precursors of ERNRQAAAANPENSRGK-amide (SEQ ID NO: 2), but isoform
3 is not.
Thus, human GDNF isoform 1 is a secretory protein that
can potentially yield three small amidated peptides by
consensus enzymatic pathways known to release peptide
amide hormones and neuropeptides from their known precursor proteins. This is a rare combination of enzymatic
processing motifs and strongly suggests that GDNF isoform
1 precursor is the metabolic precursor of up to three small
ADNS peptides, in addition to the larger C-terminal domain
that is widely supposed to posses the "full biological activity" of GDNF. C-terminal amidation in natural peptides is
highly correlated with receptor mediated signal transduction: about half of the known peptide hormones and neuropeptides and C-terminal amidation is rare and almost
unknown among other peptides of biological origin.
Animal studies with synthetic peptides corresponding to
the consensus products of Isoform 1 precursor protein are
consistent with some or all of these peptides being biologically active and involved in regulation of dopamine metabolism. This is to be expected from a protein that yields
multiple biologically active regulatory peptides in a fixed
molar ratio. The fact that the different Isoforms of GDNF
precursor protein are consensus precursors of different combinations of amidated peptides in addition to GDNF, sug-

gests a reason for differential expression of three separate
isoforms (in addition to differential secretory and nuclear
routing).
According to this model, splice form 1 of human GDNF
may be post-translationally processed in vivo to yield three
small amidated peptides, as indicated in FIG. 2. These small
amidated peptides may mediate some or all of the biological
effects of GDNF. The present invention is based on the
unexpected discovery that these small amidated fragments
of the mature GDNF protein retain the biological activity of
GDNF.
Thus, the ADNS peptides of the present invention include
these three small amidated peptides, which are represented
by the amino acid sequences ERNRQAAAANPENSRGKamide; FPLPA-amide; and PPEAPAEDRSL-amide (SEQ ID
NOs:2, 3, and 4, respectively).
The ADNS peptides of the present invention are promising candidates for treatment and prevention of neurodegenerative conditions involving dopaminergic deficiencies, such
as Parkinsons disease, age-associated motor and cognitive
slowing, and other diseases and injuries to the brain. The
small ADNS peptides are easily within the range of synthetic
production methods, so that the molecules could be subjected to rigorous structure-activity studies to optimize pharmacological activities and biostability. In addition, as the
difficulties in delivering GDNF clinically may well be
related to the fact that recombinant GDNF is not properly
processed into active forms, the small ADNS peptides may
overcome some of these difficulties. Finally, small peptides
are generally much less antigenic than proteins and can be
synthesized free of the trace host protein contaminants
always present in recombinant proteins.
The small ADNS peptides of the present invention include
biologically active synthetic or recombinant ADNS peptides, ADNS peptides produced from GDNF, biologically
active ADNS peptide variants (including insertion, substitution, and deletion variants), and chemically modified
derivatives thereof. Also included are biologically active
ADNS peptide variants that are substantially homologous to
any one of the ADNS peptides having the amino acid
sequence set forth in SEQ ID NOs:2, 3, or 4.
The term "biologically active" as used herein means that
the ADNS peptide demonstrates similar neurotrophic properties, but not necessarily all of the same properties, and not
necessarily to the same degree, as the GDNF protein having
the amino acid sequence set forth in SEQ ID NO: 1. The
selection of the particular neurotrophic properties of interest
depends upon the use for which the ADNS peptide is being
administered. The ADNS peptides are biologically active
and demonstrate dopaminergic neuron survival characteristics similar to that demonstrated by the combination of
amide peptides represented by SEQ ID NOs:2, 3, or 4 using
the evaluation of dopamine neuron survival in cultures of
newborn rat midbrain dopamine neurons as an exemplary
bioassay, as discussed in the examples below.
The term "substantially homologous", as used herein,
means a degree of sequence homology to any one of the
ADNS peptides having the amino acid sequences set forth in
SEQ ID NOs:2, 3, or 4 that is preferably at least 70%, most
preferably at least 80%, and even more preferably at least
90% or even 95%.
As used herein, the term "ADNS peptide," "peptide
amide," or "amidated peptide" means a peptide comprising
the group -CONH 2 at the C-terminal end. This amidation
occurs in vivo, once the peptides are formed by the enzyme,
peptidylglycine amidating monooxygenase (PAM). The
ADNS peptides of the present invention can be readily
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obtained in a variety of ways, including, without limitation,
recombinant expression, purification from natural sources,
and/or chemical synthesis. Preferably, the ADNS peptides
can be chemically synthesized by commercial venders. The
ADNS peptides used in the present examples were synthesized using tBOC chemistry and at a single scale range
(which generates a theoretical crude yield of 500-1,000 mg
for a 10-20 mer respectively), by the Keck Biotechnology
Resource Laboratory at Yale University (New Haven,
Conn.).
ADNS peptide pharmaceutical compositions typically
include a therapeutically effective amount of at least one of
a ADNS peptide represented by SEQ ID NOs:2, 3, and 4 in
admixture with one or more pharmaceutically and physiologically acceptable formulation materials. Suitable formulation materials include, but are not limited to, antioxidants,
preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking
agents, buffers, delivery vehicles, diluents, excipients and/or
pharmaceutical adjuvants. For example, a suitable vehicle
may be water for injection, physiological saline solution, or
artificial cerebrospinal fluid (CSF), possibly supplemented
with other materials common in compositions for parenteral
administration. Neutral buffered saline or saline mixed with
serum albumin are further exemplary vehicles.
The primary solvent in a vehicle may be either aqueous or
non-aqueous in nature. In addition, the vehicle may contain
other pharmaceutically-acceptable excipients for modifying
or maintaining the pH, osmolarity, viscosity, clarity, color,
sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the vehicle may contain still other pharmaceutically-acceptable excipients for modifying or maintaining the stability, rate of dissolution, or rate of release of
ADNS peptide, or for promoting the absorption or penetration of ADNS peptide across the blood-brain barrier. Such
excipients are those substances usually and customarily
employed to formulate dosages for parenteral administration
in either unit dose or multi-dose form or for direct infusion
into the CSF by continuous or periodic infusion from an
implanted pump.
Once the therapeutic composition has been formulated, it
may be stored in sterile vials as a solution, suspension, gel,
emulsion, solid, or dehydrated or lyophilized powder. Such
formulations may be stored either in a ready to use form or
in a form, e.g., lyophilized, requiring reconstitution prior to
administration.
The optimal pharmaceutical formulation will be determined by one skilled in the art depending upon the route of
administration and desired dosage. See for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack
Publishing Co., Easton, Pa. 18042) pages 1435-1712 the
disclosure of which is hereby incorporated by reference. The
composition may also involve particulate preparations of
polymeric compounds such as polylactic acid, polyglycolic
acid, etc. or into liposomes. Hylauronic acid may also be
used, and this may have the effect of promoting sustained
duration in the circulation. Such compositions may influence
the physical state, stability, rate of in vivo release, and rate
of in vivo clearance of the present proteins and derivatives.
Other effective administration forms, such as parenteral
slow-release formulations, inhalant mists, orally active formulations, or suppositories, are also envisioned. Preferred
ADNS peptide pharmaceutical compositions are formulated
for parenteral administration, e.g., intracerebroventricular
injection. Such parenterally administered therapeutic compositions are typically in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising ADNS

peptide in a pharmaceutically acceptable vehicle. One preferred vehicle is physiological saline.
It is also contemplated that certain formulations containing ADNS peptides are to be administered orally. ADNS
peptide which is administered in this fashion may be encapsulated and may be formulated with or without those carriers
customarily used in the compounding of solid dosage forms.
The capsule may designed to release the active portion of the
formulation at the point in the gastrointestinal tract when
bioavailability is maximized and pre-systemic degradation
is minimized. Additional excipients may be included to
facilitate absorption of ADNS peptide.
Diluents, flavorings, low melting point waxes, vegetable
oils, lubricants, suspending agents, tablet disintegrating
agents, and binders may also be employed.
It is further contemplated that formulations containing
ADNS peptides are to be administered nasally. As used
herein, nasally administering or nasal administration
includes administering the formulation containing ADNS to
the mucous membranes of the nasal passage or nasal cavity
of the patient. Formulations for nasal administration include
a pharmaceutically effective amount of the peptides prepared by well-known methods, to be administered, for
example, as a nasal spray, drop, suspension, gel, ointment,
cream or powder. Administration of the ADNS-containing
formulation may also take place using a nasal tampon, or
nasal sponge.
The ADNS peptides may be administered parenterally via
a subcutaneous, intramuscular, intravenous, transpulmonary,
transdermal, intrathecal or intracerebral route. ADNS peptides that do not cross the blood-brain barrier may be given
directly intracerebrally or otherwise in association with
other elements that will transport them across the barrier. It
is preferred that the ADNS peptide is administered intracerebroventricularly or into the brain or spinal cord subarachnoid space. ADNS peptides may also be administered
intracerebrally directly into the brain parenchyma. Slowreleasing implants in the brain containing the neurotrophic
factor embedded in a biodegradable polymer matrix can also
deliver ADNS peptides. ADNS peptides may be administered extracerebrally in a form that has been modified
chemically or packaged so that it passes the blood-brain
barrier, or it may be administered in connection with one or
more agents capable of promoting penetration ADNS peptide across the barrier. For example, a conjugate ofNGF and
monoclonal anti-transferrin receptor antibodies has been
shown to be transported to the brain via binding to transferrin receptors. To achieve the desired dose of ADNS
peptide, repeated daily or less frequent injections may be
administered, or truncated ADNS peptide may be infused
continuously or periodically from a constant- or programmable-flow implanted pump. The frequency of dosing will
depend on the pharmacokinetic parameters of ADNS peptide
as formulated, and the route of administration.
Regardless of the manner of administration, the specific
dose is typically calculated according to body weight or
body surface area. For diseases involving the brain, the
specific dose is typically calculated according to the
approximate brain weight of the subject, which also may be
estimated based on body weight or body surface area.
Further refinement of the calculations necessary to determine the appropriate dosage for treatment involving each of
the above mentioned formulations is routinely made by
those of ordinary skill in the art, especially in light of the
dosage information and assays disclosed herein. Appropriate
dosages may be ascertained through use of the established
assays for determining dosages utilized in conjunction with
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appropriate dose-response data. The final dosage regimen
involved in a method of treating a specific condition will be
determined by the attending physician, considering various
factors which modify the action of drugs, e.g., the age,
condition, body weight, sex and diet of the subject, the
severity of any infection, time of administration and other
clinical factors.
ADNS peptides of the present invention may also be
employed, alone or in combination with other growth factors
in the treatment of nerve disease. For example, ADNS
peptides may be used in treating some forms of nerve
disease in combination with nerve growth factor. In addition,
other factors or other molecules, including chemical compositions, may be employed together with ADNS peptides.
In the treatment of Parkinson's disease, it is contemplated
that ADNS peptide be used by itself or in conjunction with
the administration of Levodopa, wherein the ADNS peptide
would enhance the production of endogenous dopamine and
the neuronal uptake of the increased concentration of dopamme.
As stated above, it is also contemplated that additional
neurotrophic or neuron nurturing factors will be useful or
necessary to treat some neuronal cell populations or some
types of injury or disease. Other factors that may be used in
conjunction withADNS peptides include, but are not limited
to: mitogens such as insulin, insulin-like growth factors,
epidermal growth factor, vasoactive growth factor, pituitary
adenylate cyclase activating polypeptide, interferon and
somatostatin; neurotrophic factors such as brain derived
neurotrophic factor, neurotrophin-3, neurotrophin-4/5, neurotrophin-6, insulin-like growth factor, ciliary neurotrophic
factor, acidic and basic fibroblast growth factors, fibroblast
growth factor-5, transforming growth factor-.beta., cocaineamphetamine regulated transcript (CART) and mature
GDNF; and other growth factors such as epidermal growth
factor, leukemia inhibitory factor, interleukins, interferon,
and colony stimulating factors; as well as molecules and
materials which are the functional equivalents to these
factors.
It is envisioned that the continuous administration or
sustained delivery of a ADNS peptide may be advantageous
for a given treatment. While continuous administration may
be accomplished via a mechanical means, such as with an
infusion pump, it is contemplated that other modes of
continuous or near continuous administration may be practiced. For example, chemical derivatization may result in
sustained release forms of the protein which have the effect
of continuous presence in the blood stream, in predictable
amounts, based on a determined dosage regimen. Thus,
ADNS peptides of the present invention include ADNS
peptides derivatized to effectuate such continuous administration.
ADNS peptide cell therapy, e.g., intracerebral implantation of cells producing ADNS peptides, is also contemplated. This embodiment of the present invention may
include implanting into subject's cells which are capable of
synthesizing and secreting a biologically active form of the
ADNS peptides of the present invention. Such ADNS peptide producing-cells may be cells which do not normally
produce a neurotrophic factor but have been modified to
produce ADNS peptides, or they could be cells whose ability
to produce GDNF has been augmented by transformation
with a polynucleotide suitable for the expression and secretion of ADNS peptides. In order to minimize a potential
immunological reaction in subjects, it is preferred that the
cells be of human origin.

Implanted cells may be encapsulated to avoid infiltration
of the cells into brain tissue. Human or non-human animal
cells may be implanted in subjects in biocompatible, semipermeable polymeric enclosures or membranes to allow
release of an ADNS peptide, but that prevent destruction of
the cells by the subject's immune system or by other
detrimental factors from the surrounding tissue. Alternatively, the subject's own cells, transformed ex vivo to
produce ADNS peptides, could be implanted directly into
the subject without such encapsulation.
The methodology for the membrane encapsulation of
living cells is familiar to those of ordinary skill in the art, and
the preparation of the encapsulated cells and their implantation in subjects may be accomplished. See for example,
U.S. Pat. Nos. 4,892,538; 5,011,472; and 5,106,627, the
disclosures of which are hereby incorporated by reference.
A system for encapsulating living cells is also described in
PCT Application WO 91/10425 of Aebischer et al., specifically incorporated herein by reference. See also, PCT Application WO 91/10470 of Aebischer et al.; Winn et al., Exper.
Neural., 113:322-329, 1991; Aebischer et al., Exper. Neural.,
111:269-275, 1991; and 35 Tresca et al., ASAIO, 38:17-23,
1992, the disclosures of which are hereby incorporated by
reference.
ADNS peptide gene therapy in vivo is also envisioned,
wherein a nucleic acid sequence encoding anADNS peptide
is introduced directly into the subject. For example, a
nucleic acid sequence encoding an ADNS peptide is introduced into target cells via local injection of a nucleic acid
construct with or without an appropriate delivery vector,
such as an adeno-associated viral vector. Alternative viral
vectors include, but are not limited to, retrovirus, adenovirus, herpes simplex virus and papilloma virus vectors.
Physical transfer may be achieved in vivo by local injection
of the desired nucleic acid construct or other appropriate
delivery vector containing the desired nucleic acid sequence,
liposome-mediated transfer, direct injection (naked DNA),
receptor-mediated transfer (ligand-DNA complex), or
microparticle bombardment (gene gun). It should be noted
that the ADNS peptide formulations described herein may
be used for veterinary as well as human applications and that
the term "subject" should not be construed in a limiting
manner. In the case of veterinary applications, the dosage
ranges should be the same as specified above.
As a means of further characterizing the ADNS peptides
of the present invention, antibodies can be developed which
bind to the ADNS peptides. One of ordinary skill in the art
can use well-known, published procedures to obtain monoclonal and polyclonal antibodies, or recombinant antibodies,
which specifically recognize and bind to the various ADNS
peptides of the present invention.
Other aspects and advantages of the present invention will
be understood upon consideration of the following illustrative examples. The examples are not to be construed in any
way as limiting the scope of this invention.
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The three hypothetical precursor segments (RRERNRQAAAANPENSRGKGRR (SEQ ID NO: 5); FPLPAGKR
(SEQ ID NO: 8); and KRPPEAPAEDRSLGRR (SEQ ID
NO: 7); see FIG. 3) were subjected to BLAST searches for
short, nearly identical sequences. RRERNRQAAAANPEN-
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SRGKGRR (SEQ ID NO: 15) is present in GDNF splice
forms 1 and 2. There are some sequence variations by
species, but consensus post-translational processing signals
are maintained across species. FPLPAGKR (SEQ ID NO: 8)
was found to be invariant in the available GDNF splice form
1 sequences, but does not occur in splice forms 2 and 3.
KRPPEAPAEDRSLGRR (SEQ ID NO: 7) scored hits in
splice form 1, but not in the other GDNF splice forms. There
are some sequence variations by species, but consensus
processing signals are maintained across species. Thus,
these ADNS peptides are unique to mostly splice form 1 of
GDNF and not other splice forms of the pre pro GDNF.

amine increased by over 50% (FIG. 4). Average amphetamine-evoked release was more variable, but ranged from
about 30% for 100 µg to about 45% for 30 µg. While basal
dopamine levels were about the same in all three groups,
basal metabolite levels were elevated. As shown in FIG. 5,
the major metabolites 3,4-Dihydroxy-Phenylacetic Acid
(DOPAC) and Homovanillic Acid (HVA) were increased by
about 40% (DOPAC) and 20-40% (HVA), depending upon
the dose.

Example 2

5

10

Example 4
Dopaminergic Activity of ADNS Peptides in Cell
Cultures of Rat Midbrain Dopamine Neurons
15

Synthesis of ADNS Peptides
Three peptides, designated GER9263, GER9264, and
GDR9265 (see Table 1, below) were synthesized by Keck
Biotechnology Resource Laboratory, Yale University New
Haven, Conn. Synthetic peptides can be made routinely up
to 40 residues and often, depending on sequence, up to 70
residues by this facility. All peptides were separated and
purified on a preparative C-18 or C-4 RP-HPLC system and
delivered as a lyophilized material. Yields for normal peptides under 40 residues were "guaranteed" at 50 mg or more
and at 90+% purity. Yields and purity are often higher,
varying with the peptide sequence and length. All peptides
made in the Keck facility at the 0.5 mmole scale are done by
tBOC chemistry and at a single scale range (which generates
a theoretical crude yield of 500-1,000 mg for a 10-20 mer
respectively). The purified peptides were characterized by
analytical RP-HPLC, amino acid analysis, and FAB mass
spectroscopy.
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Example 5
ADNS Peptides and Response to CNS Delivery in
an Aged Rhesus Monkey
35

TABLE 1
ADNS peptides
Peptide

Sequence

GER9263

ERNRQAAAANPENSRGK-amide (SEQ ID NO, 2)

GER9264

FPLPA-amide (SEQ ID NO, 3)

GDR9265

PPEAPAEDRSL-amide (SEQ ID NO, 4)

40

45

Example 3
Dopaminergic Activity of ADNS Peptides in
Fischer 344 Rats
Experiments were performed to test the effects of the three
ADNS peptides (GER9263, GER9264, and GDR9265) on
dopaminergic activity in normal young adult male Fischer
344 rats. The peptides were combined in a 1: 1: 1 ratio. There
were three test groups with six animals per group: vehicle
(citrate buffer), vehicle plus 30 µg peptide mixture, and
vehicle plus 100 µg peptide mixture. The vehicle or vehicle
plus peptide solutions were steriotaxically injected in equal
portions into two sites each in the right substantia nigra.
One month after drug administration, the basal levels of
dopamine and dopamine metabolites were measured by
microdialysis in the right striatum. Potassium and amphetamine evoked release of dopamine were also evaluated.
While basal levels of dopamine were not significantly
altered in the striatum, average K+ -evoked release of dop-

To further characterize the bioactivity of the peptides,
blinded samples were sent to Dr. Michael Zigmond at the
University of Pittsburgh for testing in cultures of newborn
rat midbrain dopamine neurons. Peptide mixture samples
(GER9263, GER9264, and GDR9265 combined in a 1:1:1
ratio) were compared to citrate buffer alone, two different
lots of GDNF, and Neurturin (FIG. 6). Both lots of GDNF
and the 100 ng/ml ADNS peptide mixture exerted about the
same effects in dopamine neuron survival, increasing surviva! by about 25-30% over vehicle levels. The peptide
mixture at a concentration of 50 ng/ml promoted an increase
in survival of around 10%, approximately the same effect as
100 ng/ml Neurturin, a trophic factor that is closely related
to GDNF.
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A study was performed demonstrating that a mixture of
three ADNS peptides (GER9263, GER9264, and GDR9265
combined in a 1: 1: 1 ratio) exerts pharmacological effects on
CNS nigral dopamine neurons in an aged rhesus monkey
similar to those produced by GDNF. Marked increases of
68-125% in stimulus-evoked dopamine release were measured in the putamen by in vivo microdialysis. Motor speed,
as measured in fine motor hand movements, increased by up
to 58%, into the range of young adult monkeys. General
body movements increase by 38%, indicating much higher
activity levels. The effects from unilateral treatment were
long-lasting (for at least one month) and bilateral, similar to
those resulting from GDNF treatment. Histopathological
analysis of the injection sites in the substantia nigra revealed
only mild, circumscribed pathology from the peptide injections. The pharmacological effects of ADNS peptides on
upregulating nigrostriatal dopamine system functions are
extraordinary and suggest their potential therapeutic use for
the treatment of Parkinson's disease and age-associated
movement dysfunctions.
The ADNS peptides tested in this Example are three
amidated peptides predicted to exert potent biological effects
similar to those of Glial Cell Line-Derived Neurotrophic
Factor (GDNF). The effects of GDNF on CNS dopamine
neurons fall generally into three categories: pharmacological
upregulation of dopaminergic activity, neuronal regeneration and neuroprotection. This study was designed to assess
the pharmacological effects of ADNS peptides on substantia
nigra dopamine neurons in the nonhuman primate brain. It
was previously shown that CNS delivery ofGDNF increases
stimulus-evoked dopamine release in aged rhesus monkeys
(Grondin et al., 2003). In addition, behavioral correlates of
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increased dopaminergic activity were recorded in these
animals, improved motor functions and increased motor
speed. The present study was a case report on one aged
monkey that received a 100 µg injection of ADNS peptides
into the substantia nigra of the brain and was followed for 30
days. Motor speed was measured weekly using an automated movement analysis panel (MAP) and EthoVision, a
video tracking program. Movement features were rated
weekly using a nonhuman primate clinical rating scale
(Zhang, Z. et al., "Motor slowing and parkinsonian signs in
aging rhesus monkeys mirror human aging. ", J Gerontology: Biol. Sci. SSA: 0473-8480, (2000)). Stimulus-evoked
dopamine release was analyzed by microdialysis at the 30
day time point. The animal was then euthanized and the
brain recovered for histopathological analysis.
Methods Used for Studying ADNS Peptides
Animal:
A thirty-four year old female rhesus monkey (ID# NJOS)
weighing 7 kg was used. The animal was diagnosed as
having an inoperable mammary tumor, with the attending
veterinarian suggesting that the monkey be placed in a
terminal study and euthanized for humanitarian reasons. The
animal was maintained on a 12-hour light/12-hour dark
cycle and housed individually in a cage measuring 9 square
feet, with an elevated perch, front access doors and side rear
access doors connecting the housing cage to an adjacent
activity module. The diet consisted of certified primate
biscuits given in the morning (7:30 AM), and supplemented
daily in the afternoon (1 :30 PM) with fresh fruit or vegetables. Water was available ad libitum.
All procedures were conducted in the Laboratory Animal
Facilities of the University of Kentucky, which are fully
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. Veterinarians skilled in
the health care and maintenance of nonhuman primates
supervised all animal care.
MRI Imaging:
Magnetic resonance images (MRI) were obtained on a
10.S T clinical imager (Siemens Magnetom Vision) using a
standard cross polarized extremity coil. After being sedated
with ketamine hydrochloride (-20 mg/kg; i.m.) plus atropine
sulfate (-0.04 mg/kg; i.m.), the animal was anesthetized
with sodium pentobarbital (-10 mg/kg; i.v.) and imaged to
provide stereotaxic coordinates for peptide delivery. The
animal's head was positioned in the extremity coil using an
MRI compatible stereotaxic head frame. This frame kept the
animal's head level and immobilized at the center of the
radio frequency coil using ear and mouth bars. An initial set
of coordinates was taken using the earbars, toothbar and a
zeroing bar targeted to the gum line between the two upper
middle incisors to allow replication any time the animal was
replaced in the stereotaxic apparatus.
The coil/frame assembly was then positioned to place the
animal's head at magnet isocenter. Sets of Tl-weighted
3D-FLASH images were collected for determination of the
brain coordinates (TR/TE=22/9 ms; FA=3S 0 ; FOV=96x96x
90 mm; Matrix=l28xl28x90; Nacq=2; TA=6 min 48 sec).
All images were acquired as coronal slices relative to the
brain. Antero-posterior, lateral and vertical coordinates for
stereotaxic surgery were derived from the Tl-weighted
coronal brain images. The interaural line was identified on
the scans by modified earbars containing Vitamin E. This
provided a precise reference-point, which allowed for
anteroposterior measurements to the target. Lateral measurements were determined by measuring the distance from the
sagittal sinus/third ventricle to the target site. Vertical mea-

surements were determined from the surface of the brain to
the target at the lateral coordinate.
Surgery:
Following sedation with ketamine hydrochloride (-20
mg/kg; i.m.) plus atropine sulfate (-0.04 mg/kg; i.m.), the
animal was intubated via the orotracheal method and intravenous lines secured. Then, the animal was anesthetized
with isoflurane (1-3%) and placed in an MRI compatible
Kopf stereotaxic apparatus in a ventral-lateral position as per
the coordinates previously (see Anatomical MRI above).
The animal was maintained on a heated blanket and had
cardiac and respiratory parameters monitored during the
procedure, which was carried out using sterile field conditions. Coordinates for peptide injections were determined by
MRI prior to the surgery as described above. After being
shaved, the scalp area was cleaned using antiseptic procedures with sterile 4x4 sponges soaked in Betadine® surgical
scrub followed by 70% isopropyl alcohol. This procedure
was repeated. After the alcohol dried, Betadine® prep was
applied and the animal was covered with sterile drapes.
Then, an incision was made through the scalp and the skin
and muscles overlying the skull were reflected. Small holes
were drilled in the skull directly over the target area. The
overlying meninges were removed to expose the surface of
the brain.
A 1.0 mg/ml concentration of the three-peptide mixture in
citrate buffer was used. It was sterilized by filtration prior to
injection Using MRI-guided procedures, a 27 G needle
coupled to a Hamilton syringe containing 100 µI (i.e. 100 µg)
of the peptide mixture was lowered in the right rostral SNc
(AP: 11, L: S, DV: 30 from surface of the brain). A volume
of SO µI was delivered using a nanopump at a rate of 1
µI/min. This was followed by a 20 min waiting period before
retracting the needle out of the brain (1 mm/min). The
needle/syringe assembly was then moved 1 mm caudally
and O.S mm laterally and lowered into the more caudal SNc
(AP: 10, L: S.S, DV: 29 from surface of the brain). This was
followed by a 20 min waiting period before retracting the
needle out of the brain (1 mm/min). After completion of the
injections, the scalp incision was sutured over the exposed
areas per normal procedures and the animal was given an
analgesic (buprenorphine, 0.01 mg/kg, i.m.). Vital signs
were monitored until the animal awakened, at which point
the animal was covered with warm blankets and taken back
to its cage and monitored until it was ambulatory.
Behavioral Tests:
To assess changes in motor functions, the animal was
videotaped prior to injecting the peptide mixture, and
weekly after the injection for four weeks. The videotaping
cage measured 28 in Wx32 in Hx32 in D, had a white
background wall and a clear Lexan window permitting
videotaping. The videotaping cage was illuminated by two
48 in-long fluorescent lights located 30 in above. Water (via
a cage attached bottle) was available ad libitum throughout
the session. The animal was fed fruit or vegetables after
completion of data acquisition and upon return to its home
cage.
Beginning at 1 PM, a technician entered the room and
placed small food items (e.g. g=y bears) on the ledge of
the cage to elicit the animal to stand-up and reach out for the
food. Then, the animal was videotaped for 30 minutes with
no one in the room. Following this 30-minute videotaping
period, the technician re-entered the room, stopped recording and attached a non-wired version of the monkey Movement Analysis Panel (MAP, see below) to the doorway of the
cage for a hand retrieval test. Five to six preferred small food
items (e.g. miniature marshmallows) were placed on each
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side of the panel. The animals was given 10 minutes (default
time) to retrieve the food items, at which point the tester
re-entered the room and stopped recording. This portion of
the session was videotaped, with a focus on the hands.
Starting at 2 PM, the same procedures described above were
repeated. At the end of the testing session, the animal was
returned to its home cage.
As described above, standardized videotaping procedures
were conducted pre- and post-treatment. Behavioral parameters associated with motor function were scored from coded
videotapes from 0 (normal) to 3 (severe disability) in the
following categories: rigidity, bradykinesia, posture, balance, tremor, and hand dexterity (see Zhang et al., 2000).
Rigidity is defined as a decrease in limb extension and/or
use. Motor dysfunctions were rated in half-point increments
by an experienced rater.
Distance traveled (cm) was quantified from 8-mm videotapes (SONY P6-120 MPL) using a commercially available
video tracking system EthoVision Pro (version 2.3, Noldus
Information Technology, Asheville, N.C.) coupled to a
SONY Digital 8 video cassette recorder. This system runs on
a Pentium based computer with a frame grabber card (PICOLO, Belgium), so that the analog video signal coming
from the video cassette recorder is digitized and transferred
to the computer. A window on the computer screen directly
displays the video image, and the boundaries within which
tracking took place were defined by accurately tracing the
outline of the cage in the video image, in addition, two zones
were outlined, so that the overall activity measured in the
entire cage could be analyzed in terms of vertical (top half)
or horizontal (bottom half) activity. As described above, the
animal was videotaped for 60-minute periods, pre- and
post-treatment, and the video tracks were analyzed at a rate
of 6-sample/sec. For every sample, the cage was scanned
and the position of the tracked animal was determined by
using a gray scale detection method (brightness). This
entails calibrating the software to distinguish the darkcolored animal from the background, which is then defined
as all other pixels. The back wall of the cage was painted
white to provide a background with a maximum degree of
contrast with the dark-colored primate. This automated
method relies on determining the position of the center of
mass of the animal in the cage, and the resultant x-y
coordinates extracted as a function of time are used for
calculating the movement pattern during the observation
period. These coordinates were subsequently related to
actual spatial measures by calibrating the software to the
dimension (width) of the cage, the distance traveled by the
animal were calculated in centimeters instead of pixels.
Movement Analysis Panel (MAP):
In addition, fine/hand motor movement times in retrieving
food items from a platform level placed in a receptacle
chamber were measured using an automated clear Lexan
MAP attached to the door opening of the home cage (see
Gash, D. M. et al. "An automated movement analysis panel
for upper limb motor functions in rhesus monkeys and
humans", J. Neurosci Methods 89:111-117, (1999) and
Zhang et al., 2000). The receptacle chamber is divided into
left and right halves, and is accessible on each side through
two portals (armhole portal and receptacle portal). Movement times were measured by arrays of three photodiodes
around each portal that automatically relayed to the computer when one or more beams were broken by passage of
the monkey's arm/hand. Testing was conducted in the afternoon, prior to injecting the peptide mixture, and weekly
thereafter for four weeks. Fresh fruit and vegetables were
given to the animal after completion of the testing session.

A day's testing session consisted of twelve trials, six on each
side alternating between the right and left hand.
Microdialysis Studies:
The animal underwent bilateral putamenal microdialysis
one month post ADNS peptide injection. Using the method
described below, in vivo microdialysis procedures had also
been conducted previously in the right striatum of the same
animal (date: Feb. 10, 2004; coordinates: AP: 20.5 mm, L:
10.2 mm, DV from cortex: 21 mm).
Following normal MRI-guided stereotactic procedures
(see Surgical procedures for ADNS peptide injection), custom-made CMA/11 dialysis probes with a membrane length
of 3 mm and diameter of 0.24 mm (CMA Microdialysis,
North Chelmsford, Mass.) were positioned (1 mm/min)
bilaterally in the putamen (AP: 20 mm, L: 10.5 mm, DV
from cortex: 20 mm). Probes were perfused continuously at
a rate of 1.2 µI/min with artificial cerebrospinal fluid using
a computerized multisyringe pump (World Precision Instruments). Microdialysate fractions were collected at 30 min
intervals.
Following a I-hour application of artificial cerebrospinal
fluid to collect baseline fractions, excess potassium (100
mM KC!, 47.7 mMNaCI) was then included in the perfusate
for a single 30-min fraction (t0-t30). Two hours later 250 µM
amphetamine was included in the perfusate for a single
30-min fraction (tl-t150). Three additional fractions were
collected after discontinuing amphetamine administration
(t180-t240). The incision was then closed as per normal
surgical procedures. Microdialysate fractions were analyzed
using standard high performance liquid chromatography
procedures coupled with electrochemical detection.
Tissue Collection Procedures:
Tissue biopsies were collected for possible future use. At
the end of the dialysis session, the animal was immediately
euthanized. The deeply anesthetized animal (2 ml pentobarbital, i.v.) was transcardially perfused with heparinized
ice-cold saline (6 L). Then, the brain was removed quickly,
and dropped into a container of cold saline, which was
placed on wet ice and taken back to the laboratory. Using an
ice-cold mold, the brain was sectioned into 4-mm coronal
slabs, rostral of the midbrain.
Multiple tissue punches were taken bilaterally from frozen 4-mm thick coronal tissue sections using a 14 G biopsy
needle in the caudate nucleus (n=18 per side, tissue slabs #3,
#4 and #5), putamen (n=18 per side, tissue slabs #4, #5, #6),
nucleus accumbens (n=7 per side, tissue slabs #3 and #4)
and globus pallidus (n=5 per side, tissue slabs #6). Separate
needles were used for the right and left (green tape) hemisphere. All punches were rapidly transferred to pre-weighed
storage tubes, weighed once more, and stored at -80° C.
Pictures of the punched slabs were taken to document the
punching pattern, and then they were stored at -80° C.
The midbrain was taken out as a block, which included
the cerebellum, and post-fixed for quantitative immunocytochemistry of substantia nigra dopamine neurons and TH+
processes. To do so, the midbrain was immediately
immersed in 4% paraformaldehyde in 0.1 M phosphate
buffer (pH 7.4) at 4 ° C. for three days and transferred to 15%
sucrose solution until saturated for sectioning. Then, a series
of 40 µm-thick coronal sections were cut on a frozen sliding
microtome. One out of every 12th adjacent sections was
processed for cresyl violet (Niss!) and hemotoxylin and
eosin (H & E) staining. Also, 1/i2th adjacent sections were
processed for the following staining: a) 1:1000 mouse
anti-glia fibrillary acidic protein (GFAP) antibody for astrocytes, b) 1:200 mouse anti-HLA-DR antibody for reactive
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microglia, and c) 1:1000 mouse anti-tyrosine hydroxylase
(TH) antibody for dopaminergic neurons (see Ai et al.,
2003).
Effects of ADNS Peptides on an Aged Rhesus Money
The animal recovered without problems from peptide
delivery into the right substantia nigra. No clinically observable abnormal behaviors (e.g. auto-mutilation, stereotypic
movements, dyskinesia, vomiting) were noted throughout
the 30-day study.
As described above, standardized videotaping procedures
were conducted pre- and post-treatment to assess changes in
motor functions from coded videotapes. Prior to injecting
the three-peptide mixture into the right substantia nigra, the
animal was given a cumulative score of 3.25 points on the
rating scale (See Table 2). Although the effect was variable,
this score improved (the lower the score, the better the
movement functions) by over 30% (i.e. 1 point) by the fourth
week of the study. Similarly, distance traveled (cm) measured over weekly 60-minute periods using the automated
video-tracking system (EthoVision) improved up to 38% by
the fourth week post treatment versus baseline locomotor
activity (from 7064 cm to 9780 cm). Last but not least, MAP
performance times for left hand motor were 56% faster by
week four post peptide treatment (from 0.81 sec to 0.36 sec).
Right hand performance times were already faster than the
left pre-peptide treatment. They further improved in the 4
weeks post-treatment, with performance times 14% faster
(from 0.36 sec to 0.31 sec).
In vivo microdialysis was used to investigate the dynamics of dopamine release in the basal ganglia. Measurements
were carried out in the right putamen four weeks post
peptide treatment (see FIGS. 7A and B). In particular, FIG.
7 shows the results of potassium (K+) and d-amphetamine
(d-AMPH) evoked release of dopamine measured in the
right putamen of NJ05 using microdialysis to collect
samples for neurochemical analysis. FIG. 7A shows the first
recordings made Feb. 10, 2004, several years prior to the
ADNS peptide study. In aging monkeys, dopamine evoked
release of dopamine to K+ and d-AMPH normally decreases
with increasing age. FIG. 7B shows the second set of
recordings made thirty days after ADNS peptide injections
into the right substantia nigra on Apr. 27, 2006. K + evoked
release was increased from the 2004 reading from 36.5 nM
to 82 nM. D-AMPH evoked release of dopamine increased
from 74 nM to 125 nM after ADNS peptide administration.
Thus, in comparison to measurements recorded under similar conditions two years earlier in the same animal, potassium-evoked overflow of dopamine was increased by 125%
at 30 days postADNS peptide administration (from 36.5 nM
to 82 nM). Similarly, amphetamine-induced overflow of
dopamine was increased by 68% compared to measurements
recorded two years earlier (from 74 nM to 125 nM).
Basal levels of dopamine and dopamine metabolites in the
striatum were determined from measurements in the
microdialysates prior to potassium and amphetamine stimulation. Basal dialysate levels of dopamine and HVA showed
small changes from the baseline levels two years earlier
(Table 2). However, basal levels of extracellular DOPAC
were increased by 230% at thirty days post peptide injection
compared to the earlier baseline measures (Table 3).
The histopathological response to the injection of peptides
in the nigral region was mild (see FIGS. Sand 9). In FIG.
S, one of the injection sites (arrow) is shown using standard
histochemical techniques for Niss! staining and hematoxylin
and eosin (H & E) staining Immunostaining was conducted
to assess the response of astrocytes (GFAP positive cells)
and microglia (HLA-DR positive cells) to the injections. In

FIGS. SA and B, this injection site (arrow) was just dorsal
to the substantia nigra, pars compacta (SNc). While there is
an evident response at the injection site and a smaller
satellite area (*) of reactivity dorsal to the main area, the
injury response is very circumscribed. FIG. SC shows that
reactive astrocytosis, as assessed by GFAP positive reactivity around the needle track, is minimal, approximately that
expected from a needle tract injury alone. In FIGS. SD and
E, the injury response appears similar using H & E to that
seen with Niss!. The injury response is localized and does
not seem to involve adjacent cells. Reactive microglia
(HLA-DR+cells) are a prominent constituent of the injury
response (arrow and *, FIG. SF). (In FIG. S, Cerebral
peduncle=CP; Substantia nigra reticulatia=SNr; Ventral
Tegmental Area=VTA. Scale bars are included in each
photomicrograph.) The injection site showed reactive cells
in an area about 200 µm wide by 400 µm long in Nisslstained and H & E-stained sections (FIGS. SA, B, D and E).
The response consisted of activated microglia (HLA-DR
positive cells, FIG. SF). The absence of pronounced GFAP
immunostaining (FIG. S) indicated that the injection did not
stimulate a glial reaction.
The substantia nigra pars compacta (SNc) containing the
population of dopamine neurons that degenerates in Parkinson's disease is evaluated in the series of photomicrographs
set forth in FIG. 9. In FIG. 9A, Nissl-rich neurons (arrowheads) adjacent to the peptide injection site (*) appear
normal with prominent nuclei evident in the nucleus of some
cells. Niss! staining corresponds to the presence of rough
endoplasmic reticulum in the cytoplasm and indicates cells
actively synthesizing protein. The H & E stained section in
FIG. 9B also shows neurons with normal features (arrowheads) adjacent to the injection site(*). FIG. 9C shows that
there are only a few scattered activated microglia (arrowheads showing HLA-DR positive cells) in the SNc. Large
numbers would indicate ongoing pathological processes.
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in
dopamine synthesis. The TH positive cells shown in FIG. 9D
are dopamine neurons. Their size and exuberant expression
of TH positive processes are indicative of healthy, active
cells. Scale bars are included in each photomicrograph.
Dopamine neurons in the substantia nigra appeared to be
normal (FIG. 9). Tyrosine hydroxylase immunostaining
(FIG. 9D) revealed large dopamine neuron perikarya (cell
bodies) with extensive neuritic processes. Along with the
Niss! and H & E stained sections (FIGS. 9 A and B), the
nigral cells showed features characteristic of healthy neurons. A few activated microglia (HLA-DR positive cells,
FIG. 9C) were present in the nigral region, a typical feature
of this brain region in healthy aged monkeys. Large numbers
of activated microglia would be indicative of an ongoing
disease process.
The subject in this study was a very old rhesus monkey,
34 years old. One year for a rhesus monkey is roughly
equivalent to three years of human life, making this animal
equivalent to a 100 year old person. The monkey was used
in this study because it had a terminal disease, mannnary
cancer. The closest comparable monkeys in an earlier study
treated with GDNF were 22-24 years old (Grondin et al.,
2003). They received infusions of GDNF into the brain for
24 weeks while NJ05 had a single injection of an ADNS
peptide mixture and was monitored for one month. Despite
the differences, many of the responses were comparable to
those seen to GDNF. NJ05 motor performance times on the
MAP improved within four weeks on both the right (14%)
and left (56%) sides. The improved motor speeds
approached the speeds of aged monkeys receiving GDNF
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and those of normal young adult animals. Consistent with
increased motor speed, general locomotor activity was
increased by 38% by four weeks of treatment in NJ05.
There were neurochemical changes in NJOS's brain along
with the behavioral improvements. Both potassium- and
amphetamine-evoked release were increased (125% and
68%, respectively) in the putamen in comparison to pretreatment levels. This was similar to the increased evoked
release of dopamine in response to the same stimulants in
aged rhesus monkeys treated with GDNF (Grondin et al.,
2003). Basal dialysate levels of dopamine, HVA and
DOPAC showed high variability, but were not significantly
changed in aged GDNF recipients. NJOS's basal dopamine
and dopamine metabolite levels were in the same range as
the GDNF and vehicle-treated old animals. The only dramatic change seen in this animal was in DOPAC levels,
which increased over three-fold post ADNS peptide treatment. The significance of this response is that it reflects
higher levels of dopamine metabolism in the striatum.
Histopathology was much less extensive than the damage
in the same region from the infusion ofGDNF (see Gash, D.
M. et al., "Trophic factor distribution predicts functional
recovery in parkinsonian monkeys", Ann Neurol 58(2):22433 (2005)). The dopamine neurons in the substantia nigra
appeared healthy, with numerous neuritic processes.

DNSP-17 (GER 9263), DNSP-5 (GER 9264), DNSP-11
(GER 9265), and Biotinylated DNSP-11: DNSP-17 (sequence: ERNRQAAAANPENSRGK-amide (SEQ ID NO:
2)), DNSP-5 (sequence: FPLPA-amide (SEQ ID NO: 3)):
DNSP-11 (sequence: PPEAPAEDRSL-amide (SEQ ID NO:
4)) and biotinylated DNSP-11 (bDNSP-11; sequence: biotin-PPEAPAEDRSL-amide (SEQ ID NO: 4)) were synthesized and RP-HPLC purified to >98% by AC Scientific
(Duluth, Ga.) and the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale University. Peptides were
characterized for purity and correct sequence by MALDITOF LC-MS and Edman degradation. DNSP-11 was determined to be stable, in vitro, at a variety of experimentally
relevant concentrations and temperatures, including 37° C.
in sterile pH 5 citrate buffer for 31 days.
Tissue Preparation for DNSP-11 Staining in Substantia
Nigra at Postnatal Day (PNlO):
Tissue was prepared from SD pups. Brains were rinsed in
Dulbecco's Phosphate Buffered Saline (DPBS, Gibco), and
submerged in 4% paraformaldehyde pH 7.4 for 48 hours.
Following submersion in 30% sucrose, brains were sectioned coronally (40 µm) and stored in cryoprotectant solution at - 70° C. until processed for immunohistochemistry.
DNSP-11 Treatment of Mesencephalic Cells:
Timed pregnant SD rats (Harlan) were used to obtain the
ventral mesencephalon from E14 fetuses. The dissected
tissue was collected in cold Neurobasal™ medium and
rinsed twice with cold Dulbecco's PBS. The cells were
chemically (TrypLE®) and mechanically dissociated to
yield a single cell suspension. The solution was centrifuged
at 169 g for 6 minutes and the pellet was resuspended in
Dulbecco's Modified Eagle Medium (DMEM). Cells were
plated in a 25 µL micro-island at a density of 4000 cells/µL
on poly-D-lysine coated 24-well plates (Sigma). Following
adherence, cells were supplemented with warm Neurobasal™ media containing 2 mM glutamine, lxN2 , and 100
units of penicillin/streptomycin. Neurotrophic compounds
were added at each media addition, including initial plating
and DIV 2. A dose response of the peptides (0.03 ng to 10
ng/mL) was added to a 24-well plate following media
supplementation.
MN9D Cell Cultures:
The MN9D cell line has been described by Choi (1991)
Brain Res. 552:67-76 and was a gift from Michael Zigmond.
Cells were cultured in DMEM supplemented with 10% Fetal
Bovine Serum (FBS, Hyclone), 50 U/mL penicillin and
streptomycin. For experiments, the cells were plated on
24-well poly-D-lysine in DMEM with 1% (v/v) penicillinstreptomycin. The cells were grown at 37° C. in 5% C0 2 .
Caspase-3 Activity Assay in MN9D Cells:
MN9D cells were plated to 100,000 cells/well. Cell
cultures were exposed to DNSP-11 (1 ng/mL) or buffer for
1 hour prior to 15 min 100 µM 6-0HDA exposure. Caspase-3 activity was monitored after 3 hours by fluorescence
(excitation/emission 496/520 nm) using the Enz Chek Caspase-3 kit. Protein levels of lysed cells were measured by
BCA assay (BioRad) and normalized for every experiment.
Data expressed as % control and repeated a minimum of 3
times.
Terminal dUTP Nick-End Labeling (TUNEL) Assay in
MN9D Cells:
After treatment with DNSP-11, MN9D cells were fixed
and labelled to assess degenerative nuclear changes as
indicated by the extent of high-molecular weight DNA
strand breaks. DNA fragmentation was detected by using
steptavidin-horseradish peroxidise conjugate followed by
the substrate diaminobenzidine (DAB) generating a colored
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TABLE 2
Changes in motor functions post ADNS peptides delivery into the right
substantia nigra. The reduction in the disability score means that the
motor fllilctions such as walking and balance were improving.
The locomotor activity level increases by week four also reflect
that the animal was increasing the time and distance in walking.
The Movement Analysis Panel (MAP) scores demonstrate much
faster hand fine motor movements by week 4 after treatment.

Treatment

Disability
Score (pts )/%
baseline

Locomotor
Activity
(cm)/%
baseline

Left Map
Times (sec)/%
baseline

Right MAP
times (sec)/
% baseline

Baseline
Week 1
Week2
Week3
Week4

3.25
2.00/-38%
2.00/-38%
2.50/-23%
2.25/-31 %

7064
8422/+19%
7136/+1%
6368/-10%
9780/+38%

0.81
0.86/+6%
1.09/+35%
0.75/-7%
0.36/-56%

0.36
0.45/+25%
0.39/+8%
0.34/-6%
0.31/-14%

TABLE 3

Pre-peptides
Post-peptides
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Changes in basal dialysate levels of dopamine and dopamine metabolites
in the right putamen, 30 days post ADNS peptide delivery into the right
substantia nigra. The large increase in levels of the dopamine metabolite
DOPAC indicate increase doparninergic activity. As the enzyme
(monoamine oxidase B) for metabolizing dopamine to DOPAC is on the
outer membrane of mitochondria, it also reflects either more active
mitochondria and increased nwnbers of mitochondria.
Hemisphere

30

Dopamine (nM)

HVA(nM)

DOPAC (nM)

5.6
4.9

5033
4191

127
419
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Example 6
Materials and Methods
The following materials and methods were used in the
following examples.
Materials:
Unless otherwise stated, all cell reagents and assays were
purchased from Invitrogen. All other materials and chemicals are reagent grade.
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precipitate. Ratios between apoptotic and total cells were
determined (4 random fields/well; 4 wells/group). Experiments were repeated 3 times.
Double Fluorescent Immunostaining of DNSP-11:
Floating sections were pretreated with 0.2% H 2 0 2 in
potassium phosphate buffered saline (KPBS) for 10 minutes
and blocked with 4% normal goat serum in KPBS for 1 hour.
Then, sections were incubated overnight with both rabbit
anti-hDNSP-11 antibody (1:2000, Alpha Diagnostic) and
mouse anti-TH antibody (1:1000, Chemicon) in KPBS at 4°
C. After washing with KPBS, the sections were incubated
with Alexa-488 conjugated goat anti-rabbit IgG (1:500,
Molecular Probes) and Alexa-568 conjugated goat antimouse IgG (1:500, Molecular Probes) for 3 hours. The
sections were washed extensively and visualized with a
Nikon fluorescence microscope.
Animals and Surgical Procedures for Normal and
6-0HDA-Lesioned Rats:
Fischer 344 (F344) rats were used for all experiments and
maintained under a 12 hour light/dark cycle with food and
water provided ad libitum. All procedures were approved by
the University of Kentucky Institutional Animal Care and
Use Committee following AAALACI guidelines.
Infusion Delivery of DNSP-11 or Vehicle:
Isoflurane anesthetized (1.5-2.5%) F344 rats received 5 µl
of 6 µg/µL DNSP-11 solution or citrate buffer vehicle
solution in a blinded manner. Treatment was delivered to the
nigral cell bodies using the same stereotaxic coordinates and
protocol for solution delivery as in studies of GDNF 13 .
Reverse Microdialysis:
Reverse in vivo microdialysis was accomplished using
methods and brain coordinates described by Hebert et al.
(1996) J. Pharmacol. Exper. Ther. 279:1181-1190. CMA 11
microdialysis probes with a 4.0 mm membrane length and 6
kDa molecular weight cut-off were placed within the rat
striatum.
Unilateral 6-0HDA Lesions:
The 6-0HDA solution was delivered to two injection sites
along the medial forebrain bundle (MFB) using a protocol
described by Lundblad et al. (2002) Eur. J. Neurosci.
15:120-132. Five weeks after the unilateral 6-0HDA MFB
lesion procedure, animals were grouped based on apomorphine (0.05 mg/kg, s.c.)-induced rotational behaviour: Animals with >300 rotations per 60 minutes were selected.
Lesioned animals received 5 µL of either a 20 µg/µL
DNSP-11 solution or citrate buffer vehicle solution in a
manner similar to infusion delivery in normal animals.
Neurochemical Content of Tissue:
Lesioned animals were euthanized 5 weeks after DNSP11 or vehicle infusion. The brains were sliced into 1 mm
thick sections. Tissue punches were taken from the striatum
and the substantia nigra and they were weighed, quick
frozen and stored at - 70° C. until they were assayed by high
performance liquid chromatography with electrochemical
detection as described by Hall et al. (1989) LC/GC-Mag Sep
Sci 7:258-265.
Apomorphine-Induced Rotational Behavior Testing:
Lesion severity was assessed prior to DNSP-11 treatment
using apomorphine (0.05 mg/kg, s.c.)-induced rotational
behavior. Beginning one week after DNSP-11 treatment,
apomorphine-induced rotational behavior was monitored
weekly for four weeks as described by Hoffer et al. (1994)
Neurosci Lett. 182:107-111 (1994) and Hudson et al. (1993)
Brain Res. 626:167-174 (1993).
DNSP-11 Pull-Down Analysis:
The F344 substantia nigra was homogenized in homogenization buffer (modified from York et al. (2005) FASED J.

19: 1202-4 with 20 mM HEPES, pH 7.4) and cytosolic
fraction (supernatant) collected after 30 minutes at 100,000
g. 50 µg of bDNSP-11 was incubated with fraction for 15
minutes on ice. Sample was added to streptavidin magnetic
beads (New England Biolabs), pelleted, and washed four
times in homogenization buffer. Bound proteins were eluted
by Solubilization/Rehydration Solution (7M Urea, 2M Thiourea, 50 mM DTT, 4% CHAPS, 1% NP-40, 0.2% Carrier
ampholytes, 0.0002% Bromophenol blue), and analyzed by
2D-PAGE and MALDI-TOF MS.
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Neurobiological Actions of DNSP-11
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GDNF is endogenously produced as a pre-proprotein of
211 amino acids that is processed and secreted as a mature
homodimer with a molecular weight of 32-42 kDa. The
following examples illustrate the neurobiological actions of
dopamine neuron stimulating peptide-11 (DNSP-11 ), an
11-mer peptide that has been independently predicted to be
an endopeptidase cleavage product from the human GDNF
prosequence (FIG. lOA).
FIGS. lOA and lOB illustrate the sequence origin and
homology of DNSP-11. DNSP-11 (filled) is an 11 amino
acid sequence present in the proprotein region of the 211
amino acid human preproGDNF sequence. After cleavage of
the pre-signal sequence (shaded), DNSP-11 is predicted to
be cleaved from the proprotein at flanking dibasic cleavage
sites by endopeptidases. Further predicted processing yields
the C-terminal amidated peptide. The N-terminal (striped)
and C-terminal (checkered) proprotein fragments and
mature GDNF (open) protein are shown. The sequence
figure is not drawn to scale to highlight the processing of
DNSP-11. DNSP-11 (FIG. lOB) shows high sequence
homology to the rat and mouse proGDNF sequences suggesting a conserved function.
In vivo expression of the DNSP-11 sequence in the
substantia nigra of the ventral mesencephalon from SD pups
at postnatal day 10 (PNlO) was examined. Immunostaining
for DNSP-11 in the mesencephalon of the SD pups indicated
that the sequence is present endogenously in tyrosine
hydroxylase positive (TH+) dopaminergic neurons of the
substantia nigra at PNlO ns (yellow). The DNSP-11
sequence colocalized within dopaminergic cell bodies at
PNlO.
The neurotrophic effects of DNSP-11 were studied by
comparing its effects to the well-known effects ofGDNF on
the maintenance of primary mesencephalic cell cultures
from E14 SD rat embryos. E14 SD rat embryo primary
dopaminergic neurons from the ventral mesencephalon were
grown for 5 days in vitro and neurotrophic molecules were
added at each media change, including initial plating and
day 2. GDNF (FIG. llA, open bars) and DNSP-11 (FIG.
llA, solid bars) were added at various concentrations (0.03,
0.1, 1.0 and 10 ng/ml; 10 mM citrate buffer+150 mM NaCl,
pH 5) and were seen to significantly increase TH+ neuron
counts (+SD; one-way ANOVA with Newman-Keuls post
hoc analysis, *p<0.05 and** p<0.01) Specifically, DNSP-11
increased cell survival 75% over citrate buffer control, as
indicated by immunocytochemical staining of TH+ neurons
5 days in vitro (FIG. llA). Furthermore, DNSP-11 significantly enhanced morphological changes consistent with a
neurotrophic molecule including: neurite length, total number of branches, and increased total number of TH+ cells
(Table 4; FIG. llB). These effects were similar to those
observed for GDNF in these cells, including an increase in
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the size of TH+ neurons, which was not observed for
DNSP-11 (Table 4). Photographs in FIG. llB of treated E14
primary dopaminergic neurons demonstrate that both GDNF
and DNSP-11 treated cells (0.1 ng/ml) displayed enhanced
cell survival, neurite length, and total number of branches.
In Table 1, cell survival and morphological parameters
were quantified for control (citrate buffer) and experimental
(0.1 ng/ml GDNF or 0.1 ng/ml DNSP-11) conditions. For
morphology, five fields per well (minimum of 15 cells/field;
3-4 independent experiments) were photographed at 20x
magnification and quantified using a Bioquant Image Analysis System. DNSP-11 increased cell survival and morphological parameters comparable to GDNF, including combined neurite length and total branches. Soma size was not
increased by the addition of DNSP-11. A one-way ANOVA
was used to test for significance among groups, followed by
a Newman-Keuls post hoc analysis. Significance between
control and experimental conditions was determined at
*p<0.05 and **p<0.01.

pacta (SNc). The fluorescent immunostaining for DNSP-11,
TH and the merger of photomicrographs from each showed
that TH-positive dopamine neurons populate the SNc and
the ventral tegmental area (VTA). Higher power micrographs from the SNc. DNSP-11 immunostaining revealed
uptake into the perikaryon, nucleus, and neurites of TH+
cells.
At 1.5 hrs post-injection, staining for TH+ and DNSP-11
showed overlap in the pars compacta of the substantia nigra
and some labeling in the pars reticulata, supporting potential
uptake of DNSP-11 into GABAergic neurons. Immunohistochemical staining for DNSP-11 diminished 3 hrs after
injection and was absent at 24 hrs and beyond, indicating
that there is a rapid uptake of DNSP-11 into neurons.
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Example 9
Effect of DNSP-11 on Dopamine Neurochemistry
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TABLE 4
DNSP-11

GDNF
Control

0.1 ng/ml

Control

0.1 ng/ml

Cell survival

100 ± 15

*158 ± 12

100 ± 16

*161 ± 17

Combined neurite
length (um)
Soma size (um2 )

242
n ~
171
n ~
3.8
n ~

n~8

Average branches
per neuron

n~8

12
135
± 4
135
± 0.2
135
±

**310
n ~
177
n ~
**4.7
n ~

16
106
± 4
106
± 0.2
106
±

n~7

222
n ~
168
n ~
3.1
n ~

25

n~7

11 **306 ± 23
139
n ~ 59
± 3
165 ± 5
139
n ~ 59
± 0.2 **4.4 ± 0.3
139
n ~ 59
±

To evaluate DNSP-11 's neuroprotective properties,
DNSP-11 was compared to GDNF in its protection against
6-0HDA-induced toxicity in the dopaminergic cell line,
MN9D. MN9D dopaminergic cells were incubated for 1
hour with either citrate buffer (control), 1 ng/mL of DNSP11 orGDNF prior to 100 µM 6-0HDAexposure for 15 min.
Data are +SD, one-way ANOVA with Tukey's post hoc
analysis, *p<0.05, **p<0.01, ***p<0.001 vs. control;
#p<0.05, ##p<0.01, ###p<0.001 vs. 6-0HDA. As seen in
FIGS. llC and D, 100 µM 6-0HDA significantly increased
TUNEL staining and caspase-3 activity in MN9D cells
(FIGS. llC and D). Pretreatment with DNSP-11 or GDNF
produced a significant reduction in the percent of TUNEL
positive cells and caspase-3 activity (FIGS. llC and D).
Thus both DNSP-11 and GDNF protect against 6-0HDA
toxicity as demonstrated by reductions in TUNEL staining at
24 h (FIG. llC) and caspase-3 (FIG. llD) activity at 3 h
after 6-0HDA exposure.
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Example 8
Uptake of DNSP-11 into Neurons
Additional studies were carried out to determine ifDNSP11 is actively taken up into dopamine-containing neurons in
vivo. A single administration of 30 µg of DNSP-11 was
delivered into the rat substantia nigra. Animals were euthanized at 0.5, 1.5, 4, 24 and 48 hrs after injection to visualize
distribution of DNSP-11 using antibodies raised against
DNSP-11 and the ubiquitinated form of DNSP-11. DNSP-11
antibodies labelled the cytosol and neurites of neurons in the
area of the substantia nigra within 30 minutes after injection.
DNSP-11 was taken up by neurons in both the substantia
nigra, pars reticulata (SNr) and substantia nigra, pars com-
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Prior studies with GDNF have shown robust effects on
both potassium and amphetamine-evoked release 28 days
after a single injection into the rat substantia nigra (Hebert
et al. (1997) J. Pharm. Exp. Thera. 282: 760) indicating the
functional effects of this trophic factor on dopamine signaling in the normal rat striatum. In the present experiment, 30
µg of DNSP-11 was injected into the right substantia nigra
of normal young male Fischer 344 rats. Twenty-eight days
after injection, in vivo microdialysis was performed in these
animals to investigate dopamine neurochemistry in the ipsilateral striatum. Resting levels of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)
were significantly increased by over 100% in the DNSP-11
treated rats as compared to controls (FIG. 12A). These data
indicate longer term effects of DNSP-11 on dopamine neuron function, and are analogous to prior results involving
GDNF administration in rats and nonhuman primates. Winkler et al. (1996) J. Neurosci. 16: 7206; Hebert et al. (1996)
J Pharmacol Exper Ther. 279: 1181-1190 (1996).
The in vitro studies and in vivo measures of the effects of
DNSP-11 led to an investigation of the potential neurorestorative properties of DNSP-11 to damaged dopamine neurons
in a unilateral rat model of PD. Fischer 344 rats received
dual-site unilateral injections of 6-0HDA to produce extensive destruction of the ascending dopaminergic system that
resulted in a greater than 99% depletion of striatal dopamine
content ipsilateral to the site of the 6-0HDA injections. Rats
were tested 3-4 weeks after the injection of 6-0HDA using
low-dose (0.05 mg/kg, i.p.) apomorphine-induced rotational
behavior. In rats that rotated greater than 300 tums/60
minutes, 30 µg of DNSP-11 was injected into the ipsilateral
substantia nigra. DNSP-11 produced a significant -50%
decrease in apomorphine-induced rotational behavior that
was significant 1 week after administration and this effect
was maintained for at least 4 weeks after DNSP-11 (FIG.
12B). At 5 weeks, the substantia nigra and striatum from
each rat was analyzed by high performance liquid chromatography coupled with electrochemical detection. A single
injection of DNSP-11 was found to significantly increase
levels of dopamine and the dopamine metabolite, DOPAC,
by -100% in the substantia nigra, indicating that DNSP-11
has a powerful neurotrophic-like restorative effect on dopamine neurons in this animal model of late stage PD (FIG.
12C).
As shown in FIG. 12A, 28 days after DNSP-11 or citrate
buffer vehicle was delivered to the nigral cell bodies, the
DNSP-11 treatment group showed significantly higher basal
neurochemical concentrations of DA, DOPAC and HVA.
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Basal DA increased from 26.0±2.7 nM in the vehicle treatment group to 45.8±7.7 nM in the DNSP-11 treatment group
(tc 31 )=2.255, p=0.0314). Basal concentrations of DOPAC
increased from 3355±338 nM in the vehicle group to
6544±836 nM in the DNSP-11 group (tc 31 )=3.293,
p=0.0025), and HVA, increased from 2419±251 nM with
vehicle treatment to 4516±502 nM with DNSP-11 treatment
(t(3o)=3.588, p=0.0012). All data were analyzed using a
two-tailed unpaired t-test * p<0.05. FIG. 12B shows the
results of assessment of apomorphine (0.05 mg/kg) induced
rotational behavior prior to infusion treatment (Pre) and
once weekly for 4 weeks after DNSP-11 or vehicle treatment. Drug-induced rotational behavior is expressed as a
percentage of vehicle treatment and showed a significant
decrease in rotational behavior beginning one week after
DNSP-11 treatment that lasted for all 4 weeks post DNSP11. The data were analyzed using a one-way ANOVA for
repeated measures (Fc4 •39 )=4.807, p=0.0005) with Bonferroni's multiple comparison test * p<0.05, ** p<0.01, ***
p<0.001. FIG. 12C shows that DNSP-11 treatment significantly increased levels of DA, (74%) and DOPAC (132%) in
the substantia nigra of unilateral 6-0HDA-lesioned rats. DA
content was determined to be 34.7±6.4 ng/g in the vehicle
treatment group and 59.1±7.3 ng/g in the DNSP-11 treatment group (tc 13 )=2.521, p=0.0265). DOPAC tissue content
was determined to be 7.10±1.40 ng/g in the vehicle treatment group and 16.48±4.01 ng/g (tc 13 )=2.33, p=0.0364) in
the DNSP-11 treatment group. All data were analyzed using
a two-tailed unpaired t-test, * p<0.05.

GDNF (FIG. 13; F-Flow through, E-Elution). Moreover, the
absence of interaction between GFRal with DNSP-11 is
supported by ELISA.
A gel filtration study was performed using a 120 mL
Sephacryl S-200 column at a constant 1 mL/min flow rate.
Individual 300 µM solutions of GAPDH (-150 kDa; FIG.
14, dotted line) or GDNF (-30 kDa; FIG. 14, dashed line)
eluted at expected retention times for their sizes of 50 min
(FIG. 14, star) and 64 min (FIG. 14, pound sign), respectively. When a pre-equilibrated (1 h), equimolar solution of
GAPDH and GDNF was analyzed by gel filtration chromatography, two equally intense peaks were observed (FIG. 14,
solid line) with retention times identical to the individual
solutions. These data demonstrate that GDNF does not
interact with GAPDH in solution, thereby providing evidence that DNSP-11 has an independent mechanism of
action relative to mature GDNF.
Taken together, these data indicate that DNSP-11 exhibits
potent neurotrophic actions analogous to GDNF, but likely
signals through pathways that do not directly involve the
GFRal receptor.
The foregoing examples demonstrate that DNSP-11
shares many physiological and neurotrophic properties with
mature GDNF, including neuroprotection and promoting
differentiation in primary dopamine neuron cell cultures;
increasing dopamine release and metabolism in vivo; and
decreasing apomorphine-induced rotations and enhancing
dopamine function in the substantia nigra of 6-0HDA
lesioned rats.
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Example 11

Interaction of DNSP-11 with Protein Partners

DNSP-11 Solubility and Stability

In order to identify the interactions of DNSP-11 with
protein partners and to gain insight into the cellular mechanisms involved with the actions of DNSP-11, a pull-down
assay was performed with homogenate from isolated substantia nigra of normal young Fischer 344 rats. Cytosolic
and membrane fractions were collected and incubated with
biotinylated DNSP-11 for 30 minutes. Bound proteins were
pulled down by strepavidin magnetic beads, extensively
washed to remove non-specific binders, eluted with solubilization/rehydration buffer and separated by 2D-PAGE.
Specifically, a solution of 25 µL GFRal (1 mg/mL) was
incubated with 50 µL of Dynabeads® (Invitrogen) in wash
and bind buffer (O. lM sodium phosphate, pH 8.2, 0.01 %
Tween® 20) for 10 minutes at room temperature. The beads
were then washed three times in 100 µL of wash and bind
buffer. 2 µg of GDNF was added and incubated for 1 hour
at 4° C. 25 µL GFRal (1 mg/mL) was incubated with 40 µg
of biotinylated DNSP-11 (bDNSP-11) for 1 hour at 4° C.
They were then added to 50 µL of hydrophilic streptavidin
magnetic beads (New England Bio labs) and incubated for an
hour at 4° C.
Several spots were observed in both the cytosolic and
membrane fractions, indicating that DNSP-11 is able to bind
proteins found within the substantia nigra. To identify these
binding partners, protein bands were excised from the gels,
trypsin digested, and analyzed by MALDI-TOF mass spectrometry. From these preliminary studies, approximately 20
proteins were identified. Of these, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a protein with a link to PD
and apoptosis, was identified. This result was confirmed by
in vitro pull down assays with pure GAPDH and DNSP-11.
In addition, a pull-down assay ofDNSP-11 with GFRal
indicated that the two molecules do not interact, like mature
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The backbone secondary structure of DNSP-11 was
examined using circular dichroism spectroscopy in the farUV region (CD; University of Kentucky Center of Structural
Biology). The DNSP-11 spectrum (FIG. 15A) displayed a
broad minimum mean residue ellipticity (MRE) at 200 nm,
indicative of a peptide that it is dynamic and samples
multiple confirmations. Small shoulders between 208-230
nm indicate that DNSP-11 appears to be sampling polyproline II and other helical structures. Collectively, the spectrum ofDNSP-11 shows that it has characteristics of typical
small, soluble, functional peptides of similar length.
Reverse Phase HPLC(RP-HPLC; FIG. 15B); University
of Kentucky Center of Structural Biology) and electro spray
mass spectrometry (University of Kentucky Mass Spectrometry Facility) were used to monitor at the stability of
DNSP-11. DNSP-11 was stored in citrate buffer (10 mM
Citrate+150 mM NaCl, pH 5.0) at -80° C. and 37° C. for 30
days. These temperatures were chosen based on their relevance to long term storage and use in future studies. The
results of these studies showed that the peptides were stable
at both temperatures for one month without any appreciable
loss of peptide (FIG. 15C).
Our analysis of the effects of DNSP-11 on dopamine
neurons in the nigrostriatal system of the brain of young
adult F344 rats at 28 days following a single injection of the
peptide, demonstrated a surprising effect, i.e., an increase in
basal tissue levels of the dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC, see FIG. 16). The 100%
increase in DOPAC was unprecedented in our numerous
experiments over the past 20 years. In fact, we have never
seen a dopamine-altering agent, which increases the metabolism of dopamine by 100% and this effect was seen to persist
for one month after a single injection of DNSP-11 into the
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substantia nigra, which is the source of the dopaminecontaining fibers measured in the striatum. GDNF, which
augmented the evoked release of dopamine by over 100%,
increased basal levels of DO PAC by only 20-25% in young
and aged rats (Herbert et al. J. Pharmacol. Exp. Therapeut.
(1996) 279:1181-1190, and Hebert and Gerhardt, J. Pharmacol. Exp. Therapeut. (1997) 282:760-768). Based on the
results presented herein, and the knowledge that DOPAC is
produced when dopamine is metabolized by monoamine
oxidase B, (an enzyme on the outer membrane ofmitochondria (Edmondson et al, Curr. Med. Chem (2004) 11(15:198393) and then the product of this reaction is metabolized by
aldehyde dehydrogenase (which resides in the cytosol of
cells) we reasoned that DNSP-11 increases mitochondrial
functions and thereby increases monoamine oxidase levels.
The following examples address this.

observed into neurons in both areas. Pyramidal neurons in
the cortex accumulated DNSP-11.
In summary, DNSP-11 is taken up within 30 minutes by
neurons in all brain areas evaluated. The uptake sites appear
5

to be specific for axons, dendrites, synaptic terminals and
perikarya of nerve cells. DNSP-11 immunostaining is found
in the cytoplasm and then in the nucleus. The half-life of
DNSP-11 in the rat brain is under 24 hours. The areas of the

10

brain studied (substantia nigra, striatum, hippocampus and
cortex) have major roles in cognitive and motor functions.
Tropic actions of DNSP-11 could protect these brain areas
from injury and/or promote restoration from disease and
injury processes.

15

Example 13

Example 12
20

DNSP-11: Distribution, Uptake and Half-Life in the
Brain
To assess the distribution, uptake and degradation of
DNSP-11 in the brain, young adult male F344 rats, as a test
organism, received injections of 30 µg DNSP-11 in the
substantia nigra, hippocampus or cortex. They were euthanized by anesthesia overdose at various time points from 30
minutes to 48 hrs later and perfused through the heart with
saline followed by paraformaldehyde.
Our standard published procedures for immunocytochemical staining were used (e.g. Gash D M et al., J Comp
Neural. 1995 Dec. 18; 363(3):345-58, Grondin et al., 2002;
Ai et al., 2003). A polyclonal antibody was generated against
DNSP-11 in rabbits (Alpha Diagnostic International, San
Antonio, Tex.). Endogenous peroxidases were inactivated
by incubation with 0.2% hydrogen peroxide (H 2 0 2 ) for 10
minutes and background blocked with 4% normal serum,
1% bovine serum albumin (BSA) for 1 hour. Free floating
sections were incubated in primary antisera. Sections were
then exposed to the appropriate biotinylated IgG (Vecto
Labs, Burlingame, Calif.) for 1 hour and then incubated in
avidin-biotin-peroxidase complex using Elite ABC
Vectastain Kits (Vector Labs) for 1 hour. Some sections were
double-labeled using procedures following our published
procedures for immunocytochemical staining to identify
cells with two markers (e.g. Ai et al., 2003).
Controls for immunostaining included the omission of
primary antibodies and replacement of primary antibodies
with normal serum of the same species.
Results: A 30 µg bolus of DNSP-11 injected into the
mid-substantia nigra region using stereotaxic procedures
spreads -3 mm in the anterior-posterior plane and up to -2
mm in the medial-lateral plane (FIG. 17) to cover most of the
pars compacta component of the nigra. DNSP-11 is taken up
in the first 30 minutes following injection by neurons and
their axonal and dendritic processes. It is found in the
cytoplasm and then perinuclear area and nucleus. At 24
hours after injection, some residual DNSP-11 can still be
detected. There was no evidence of DNSP-11 by 48 hours
post peptide administration.
Stereotaxic injections of 30 µg DNSP-11 were also made
into the striatum, hippocampus and cortex. Uptake was
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DNSP-11 Induced Changes in Genes Regulating
Mitochondria/Functions
Changes in expression of mitochondrial-associated genes
in the substantia nigra (SN) of three young adult (5 month
old) male F344 rats 48 hours following bilateral intranigral
injections of DNSP-11 into the substantial nigra was
assessed as follows.
A 3 µg/µl DNSP-11 peptide solution was prepared in
citrate buffer and filter sterilized. Stereotaxic injections were
made of 30 µg DNSP-11 in 10 ul citrate buffer into the
substantia nigra on each side of the brain. Controls received
10 µg injections of vehicle. Forty-eight hours later, the
animals were euthanized, the brains quickly recovered and
sectioned so that the bilateral SN could be dissected out as
one block of tissue and snap frozen in liquid nitrogen. RNA
was extracted from the SN samples for gene array analysis,
which was conducted on Affymetrix Version II chips. A gene
chip was run for each of the six rats: three bilateral vehicle
recipients, three bilateral 30 µg DNSP-11 recipients.
Genes regulating mitochondrial functions were identified
as the subset of genes on the microarray in the peptidetreated group having expression levels that were significantly increased or decreased as compared to the controls
(Table 5). Fourteen genes were significantly up-regulated
and five were significantly down-regulated in DNSP-11
recipients. One gene with increased expression was Monoamine Oxidase B, a finding consistent with the higher
DOPAC levels mentioned earlier. A number of other genes
with increased expression are associated with protection
against oxidative damage: glutathione/glutaredoxin, glutathione peroxidase and thioredoxin (Koehler et al., Antioxid
Redox. Signal., 8(5-6):813-22 (2006); Comhair & Erzurum
Antioxid Redox Signal., 7(1-2):72-9. (2005)). Catalase is an
important enzyme converting the strong oxidant hydrogen
peroxide to water- and oxygen (Calderon IL et al., Catalases
are NAD(P)H-dependent teliurite reductases. PLoS ONE.
1:e70 (2006 Dec. 20)). Peroxyredoxin is another antioxidant
(Rhee, Chae & Kim, Free Radie Biol Med. 2005 Jun. 15;
38(12):1543-52. Epub (2005 Mar. 24)). Increased levels of
Park 7 (DJ-1) are protective against Parkinson's disease
(Thomas & Beal, Hum Mal. Genet. 16 Spec No. 2:R183-94
(2007 Oct. 15)) and increase levels of Presenilin 1 are
believed to be protective against Alzheimer's disease (Das,
Front Biosci. 13:822-32 9 (2008 Jan. 1)). In both instances,
it is a decreased or mutant form of the gene that is closely
linked to neurodegenerative diseases. The cytochrome c
oxidase subunits are components of the terminal respiratory
complex producing energy via oxidative phosphorylation.

us
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TABLE 5

Changes in ex12ression level 12ost DNSP-11 delivea
SYMBOL DESCRIPTION
GLRX2
CASP8
TXN2
MAOB
COX6A2
GPX7
CAT
PRDX5
PSENl
CASP3
COX17
PARK.7
COX6Bl
NDUFA7
APP
MAPK9
MAPKlO
BACEI
MAP2K4

glutaredoxin 2
caspase 8, apoptosis-related cysteine
peptidase
thioredoxin 2
monoarnine oxidase B
cytochrome c oxidase subunit Via
polypeptide2
glutathione peroxidase 7
catalase
peroxiredoxin 5
presenilin 1 (Alzheimer disease 3)
caspase 3, apoptosis-related cysteine
peptidase
COX! 7 cytochrome c oxidase assembly
homolog (S. cerevisiae)
DJ-1 protective against Parkinson's disease
cytochrome c oxidase subunit Vib
polypeptide 1 (ubiquitous)
NADH dehydrogenase (ubiquinone) 1
alpha subcomplex, 7, 14.5 kDa
amyloid beta (A4) precursor protein
(peptidase nexin-11, Alzheimer disease)
mitogen-activated protein kinase 9
mitogen-activated protein kinase 10
beta-site APP-cleaving enzyme 1
mitogen-activated protein kinase kinase 4

P-VALUE FOLD CHANGE

PEPTIDE

CONTROL

3618.7
219.4

3472.2
178.1

<0.001
0.006

1.09
1.25

1511.9
2199.8
814.1

1378.5
1974.2
520.6

0.010
0.012
0.014

1.10
1.13
1.75

194.2
2828.2
5569.8
673.5
421.4

183.8
271a.O
4790.1
563.2
367.5

O.G15
O.G15
0.020
0.022
0.024

1.19
1.09
1.13
1.16
1.18

2326.1

2017.8

0.025

1.11

5299.2
7869.7

5159.4
7536.6

0.032
0.044

1.02
1.04

3125.4

2943.0

0.046

1.07

9734.4

10117.2

0.006

-1.08

770.7
505.0
451.6
2422.4

930.0
552.8
510.6
2744.4

0.007
0.008
0.016
0.043

-1.21
-1.08
-1.09
-1.12

The caspases having increased expression are associated
with apotosis (Kataoka, Crit. Rev Immunol. 25(1):31-58
(2005); Vassar, Neuron 54(5):671-3 (2007)). Without wishing to be bound by theory, the increased expression of low
levels capases may reflect a nonspecific inflammatory reaction to the mild physical injury induced by the needle track
and injection of material into the substantia nigra.
The foregoing results indicate that DNSP-11 treatment
significantly effects the expression of genes regulating mitochondrial functions. The changes in gene expression would
be neuroprotective against free radical oxidative damage to
mitochondria. This would decrease mitochondrial wear and
tear from oxidative respiratory processes producing energy,
increasing the functional lifespan of mitochondria in a
neurons and synapses.

Mitochondrial respiration was assessed using a miniature

3

° Clark-type electrode, in a sealed, thermostatic and continu-
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Example 14
DNSP-11 Increases State III
Mitochondria/Respiration in the Rat Nigrostriatal
System
As our previous studies had demonstrated that injections
of 30 µg DNSP-11 into the substantia nigra had marked
effects 28 days post administration with elevated levels of
dopamine and dopamine metabolites in the nigrostriatal
system (substantia nigra and its projections to the striatum),
we quantified the effects of DNSP-11 on mitochondria
respiration and enzyme activity in the nigrostriatal system of
young adult F344 rats at 28 days post injection.
Six five-month-old male F344 rats received bilateral
intranigral injections of 30 µg DNSP-11. Six age and sexmatched controls received injections of the same volume of
vehicle (citrate buffer). Twenty-eight days after test material
administration, the animals were euthanized by C0 2 anesthesia and the brain samples rapidly dissected. The striatum
and substantia nigra were isolated quickly and carefully
using a rat brain matrix for F344 rats.
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ously stirred chamber. Mitochondria were added to the
chamber to yield a final protein concentration of 1 mg/ml.
The substrate concentrations were 5.0 mM/2.5 mM for
glutamate/malate and pyruvate/malate or 10 mM for succinate +2.5 µM rotenone or a-glycerophosphate. State 3
respiration was initiated by the addition of 150 l]mols ADP.
The respiratory control ratio was calculated as respiration in
the presence of ADP (state 3)/respiration in absence of ADP
(state 4). ADP/O ratios were determined by dividing the
amount of ADP phosphorylated during State III respiration
by the amount of oxygen consumed. NAD-linked substrates,
e.g. glutamate and pyruvate, utilize complexes I, III, IV in
their oxidation, succinate utilizes complexes II, III, IV and
a-glycerophosphate utilizes III, IV. Thus impaired oxidation
ofNAD-linked substrates, but normal oxidation of succinate
or a-glycerophosphate implies a defect at the level of
complex I. Impaired oxidation of both NAD-linked and
succinate oxidation implies a defect in both complex I and
II and/or in complex III and IV which can be elucidated by
the use of a-glycerophosphate.
The chamber was also equipped with fluorescence/absorbance probes which allow us to also measure simultaneously
ROS production in real-time with all other parameters. ROS
production was measured using the H 2 0 2 indicator dichlorodihydrofluorescein diacetate (H 2 DCFDA, Molecular
Probes). Ten µM H 2 DCFDA, which is made fresh before
each use, was added to the chamber and the relative amount
of mitochondria) H 2 0 2 and free radical production measured
as an increase in fluorescence. Again the same rationale as
above can be used to pinpoint the source of ROS production.
Additionally, ROS production was monitored over time in a
Synergy HT plate reader or a Shimadzu RF-5301 spectrofluorimeter with stirred and water-jacketted cuvett holders
(excitation 490 µm, em1ss10ns 526 l]m; ex55011m,
em59011m, respectively) at 3 7° C. for 15 min in the presence
of 10 µM H 2 DCFDA or Amplex Red, a H 2 0 2 indicator that
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is extramitochondrial. Controls include the addition of the
electron transport chain inhibitor antimycin (complex III
inhibitor, yields maximum ROS production independent of
ll W), oligomycin (inhibits ATPase yielding maximum
llW-dependent ROS production) and the uncoupler FCCP
(inhibits all llW-dependent ROS production).
The mitochondria are freeze-thawed and sonicated three
times for measuring all the complexes activities. Complex I
(NADH dehydrogenase) assay is performed in 2.5 mM
KP04 buffer (pH 7.2) containing mitochondrial protein (6
µg), 5 mM MgC1 2 , 1 mM KCN, 1 mg/ml BSA, and 150 µM
NADH at 30° C., the reaction initiated by addition of
coenzyme Q-1 (50 µM). In this reaction ubiquinone 1 was
the final electron acceptor. The decrease in NADH absorbance at 340 rim was monitored. The assay was also
performed in the presence ofrotenone (10 µM) to determine
the rotenone-insensitive and the rotenone-sensitive complex
I enzyme activity. Complex II (succinate dehydrogenase)
activity was measured by the rate of reduction of 2,6Dichloroindophenol. The reaction mixture contained 100
mM KP04 buffer, 20 mM succinate, 10 µM EDTA, 0.01 %
Triton, 1 µg/100 µl coenzyme Q2 containing mitochondria)
protein (6 µg) at 30° C. and the reaction was initiated by the
addition of 0.07% 2,6-Dichloroindophenol. Decreased in
absorbance was monitored at 600 rim. Complex IV (cytochrome c oxidase) activity was measured in 10 mM KP04
buffer and 50 µM reduced cytochrome c. The reaction was
initiated by addition of 6 µg mitochondria) protein. Rate of
oxidation of cytochrome c was measured by measuring the
decrease in absorbance of reduced cytochrome c, observed
at 550 nm.
As shown in FIG. 18, there was a trend towards an
increase in State III oxidative phosphorylation at 28 days
post treatment in the substantia nigra. However, with an n=2,
the difference was not significant with a two-tailed t-test.
The effects reached statistical significance in the striatum,
which is heavily innervated by dopamine fibers from the
substantia nigra forming synapses on striatal medium spiny
neurons. Evidence described in Example 12 indicates that
DNSP-11 was taken up within 30 minutes into neuritic
processes and cell bodies of neurons. Soon thereafter, immunoreactive DNSP-11 was found in the nucleus. The effects
at 28 days on dopamine and metabolite levels and on
mitochondria demonstrate that DNSP-11 treatment initiates
genetic changes that last for long periods, at least one month,
and without wishing to be bound by theory, this may occur
perhaps through receptors involving transcribing factors.
Within 30 minutes following a 30 ug injection of DNSP11 into the F344 rat substantia nigra, the broad distribution
of the compound through the substantia nigra (SN) region of
the midbrain was evident (FIG. 17, panels A, B). At higher
magnification (FIG. 17 panels C, D) uptake of the peptide by
neurons (arrows) could be discerned. At very high magnification (FIG. 17 panel E), punctuate-immunoreactive staining of DNSP-11 was present in neuritic processes, cytoplasm and the perinuclear area of the cell body (arrows). The
pattern of immunoreactivity was similar at 90 minutes post
injection (FIG. 17 panel B), with prominent labeling in
DNSP-11 in cells and neuritic processes (FIG. 17, panel D).
Immunostaining was more sensitive using fluorescent techniques (FIG. 17, panel F), highlighting DNSP-11 immunoreactivity in the cytoplasm and nuclei of neurons. The cells
in F were double-labeled for the neuronal marker NeuN and
DNSP-11.
By improving mitochondrial functions in neurons and
their synapses, DNSP-11 treatment could significantly
restore neural networks affected in neurodegenerative dis-

eases, including Alzheimer's disease and Parkinson's disease, improving cognitive functions in the former and
improved motor functions in the latter.
Example 15
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The in vitro studies and in vivo measures of the neurotrophic/mitochondrogenic effects of DNSP-11 led us to
investigate the potential neurorestorative properties of
DNSP-11 to damaged dopamine neurons in a unilateral rat
model of PD.
Fischer 344 rats received dual-site unilateral injections of
6-0HDA to produce extensive destruction of the ascending
dopaminergic system that resulted in a greater than 99%
depletion of striatal dopamine content ipsilateral to the site
of the 6-0HDA injections. Rats were tested 3-4 weeks after
the injection of 6-0HDA using low-dose (0.05 mg/kg, i.p.)
apomorphine to induce rotational behavior. In rats that
rotated greater than 300 turns/60 minutes, 30 µg ofDNSP-11
was injected into the ipsilateral substantia nigra. DNSP-11
produced a significant -50% decrease in apomorphineinduced rotational behavior that was significant 1 week after
administration and this effect was maintained for at least 4
weeks after DNSP-11 (FIG. 19A). At 5 weeks, the substantia
nigra and striatum from each rat was analyzed by high
performance liquid chromatography coupled with electrochemical detection. A single injection of DNSP-11 was
found to significantly increase levels of dopamine and the
dopamine metabolite, DOPAC, by -100% in the substantia
nigra, supporting that DNSP-11 has a powerful neurotrophic-like/mitochondrogenic restorative effect on dopamine neurons in this animal model of late stage PD (FIG.
19B).
In summary, the evidence reported in this patent application demonstrates the ability of DNSP-11 treatment to
improve mitochondrial functions and supports the ability of
DNSP-11 treatment to promote behavioral restoration in
Alzheimer's disease, Parkinson's disease and aging processes.
Our results demonstrate that DNSP-11 is taken up by
neurons in the cortex, hippocampus and substantia
nigra, areas important in cognitive and motor functions;
Our results demonstrate that DNSP-11 significantly
increases the expression of genes associated with mitochondrial functions in the brain, including genes for
proteins that protect mitochondria from oxidative damage leading to functional deterioration;
Our results demonstrate that DNSP-11 increases energy
production in brain mitochondria for extended periods.
Increased energy production in mitochondria in synapses
is posited to promote restoration of neural circuitry
leading to restoration of cognitive and motor functions.
While the present invention has been described with
reference to specific embodiments, this application is
intended to cover those various changes and substitutions
that may be made by those of ordinary skill in the art without
departing from the spirit and scope of the appended claims.
The publications discussed herein are provided solely for
their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission
that the present invention is not entitled to antedate such
publication by virtue of prior invention. Further, the dates of
publication provided may be different from the actual publication dates, which may need to be independently confirmed. All publications cited herein are hereby incorporated
by reference in their entirety.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

15

SEQ ID NO 1
LENGTH, 134
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE,

1

Ser Pro Asp Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg
1
5
10
15
Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg
20
25
30
Gly Gln Arg Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu
35
40
45
Asn Val Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile
50
55
60
Phe Arg Tyr Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp
65
70
75
80
Lys Ile Leu Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys
85
90
95
Val Gly Gln Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser
100
105
110
Phe Leu Asp Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala
115
120
125
Lys Arg Cys Gly Cys Ile
130

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH, 17
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 2
Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly
1
5
10
15
Lys

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 5
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 3
Phe Pro Leu Pro Ala
1

<210>
<211>
<212>
<213>
<220>
<223>

5

SEQ ID NO 4
LENGTH, 11
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 4
Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu
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-continued
5

1

<210>
<211>
<212>
<213>
<220>
<221>
<222>

10

SEQ ID NO 5
LENGTH, 402
TYPE, DNA
ORGANISM, Homo sapiens
FEATURE,
NAME/KEY, CDS
LOCATION, (1) .. (402)

<400> SEQUENCE, 5
tea cca gat aaa caa atg gca gtg ctt cct aga aga gag egg aat egg
Ser Pro Asp Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg
1
5
10
15

48

cag get gca get gee aac cca gag aat tee aga gga aaa ggt egg aga
Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg
20
25
30

96

ggc cag agg ggc aaa aac egg ggt tgt gtc tta act gca ata cat tta
Gly Gln Arg Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu
35
40
45

144

aat gtc act gac ttg ggt ctg ggc tat gaa ace aag gag gaa ctg att
Asn Val Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile
50
55
60

192

ttt agg tac tgc age ggc tct tgc gat gca get gag aca acg tac gac
Phe Arg Tyr Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp
65
70
75
80

240

aaa ata ttg aaa aac tta tee aga aat aga agg ctg gtg agt gac aaa
Lys Ile Leu Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys
85
90
95

288

gta ggg cag gca tgt tgc aga ccc ate gee ttt gat gat gac ctg tcg
Val Gly Gln Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser
100
105
110

336

ttt tta gat gat aac ctg gtt tac cat att eta aga aag cat tee get
Phe Leu Asp Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala
115
120
125

384

aaa agg tgt gga tgt ate
Lys Arg Cys Gly Cys Ile
130

402

<210>
<211>
<212>
<213>

SEQ ID NO 6
LENGTH, 211
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE,
Met Lys Leu Trp Asp Val Val Ala Val Cys Leu Val Leu Leu His Thr
1
5
10
15
Ala Ser Ala Phe Pro Leu Pro Ala Gly Lys Arg Pro Pro Glu Ala Pro
20
25
30
Ala Glu Asp Arg Ser Leu Gly Arg Arg Arg Ala Pro Phe Ala Leu Ser
35
40
45
Ser Asp Ser Asn Met Pro Glu Asp Tyr Pro Asp Gln Phe Asp Asp Val
50
55
60
Met Asp Phe Ile Gln Ala Thr Ile Lys Arg Leu Lys Arg Ser Pro Asp
65
70
75
80
Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg Gln Ala Ala
85
90
95
Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg Gly Gln Arg
100
105
110
Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu Asn Val Thr
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39
-continued
115

120

125

Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr
130
135
140
Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu
145
150
155
160
Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln
165
170
175
Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp
180
185
190
Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala Lys Arg Cys
195
200
205
Gly Cys Ile
210

<210>
<211>
<212>
<213>

SEQ ID NO 7
LENGTH, 192
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 7
Phe Pro Leu Pro Ala Gly Lys Arg Pro Pro Glu Ala Pro Ala Glu Asp
1
5
10
15
Arg Ser Leu Gly Arg Arg Arg Ala Pro Phe Ala Leu Ser Ser Asp Ser
20
25
30
Asn Met Pro Glu Asp Tyr Pro Asp Gln Phe Asp Asp Val Met Asp Phe

35

40

45

Ile Gln Ala Thr Ile Lys Arg Leu Lys Arg Ser Pro Asp Lys Gln Met
50
55
60
Ala Val Leu Pro Arg Arg Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn
65
70
75
80
Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg Gly Gln Arg Gly Lys Asn
85
90
95
Arg Gly Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly
100
105
110
Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly
115
120
125
Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu Lys Asn Leu
130
135
140
Ser Arg Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln Ala Cys Cys
145
150
155
160
Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu
165
170
175
Val Tyr His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys Ile
180
185
190

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 8
LENGTH, 8
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 8
Phe Pro Leu Pro Ala Gly Lys Arg
1

5
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-continued

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 9
LENGTH, 14
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 9
Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu Gly Arg Arg
1
5
10

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 10
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 10
Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly
1
5
10
15
Lys Gly Arg Arg
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 11
LENGTH,
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 11
Phe Pro Leu Pro Ala Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

5

SEQ ID NO 12
LENGTH, 12
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 12
Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu Gly
1
5
10

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 13
LENGTH, 18
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 13
Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly
1
5
10
15
Lys Gly

<210>
<211>
<212>
<213>

SEQ ID NO 14
LENGTH, 16
TYPE, PRT
ORGANISM, Artificial Sequence
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-continued

<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide
<400> SEQUENCE, 14
Lys Arg Pro Pro Glu Ala Pro Ala Glu Asp Arg Ser Leu Gly Arg Arg
1
5
10
15

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 15
LENGTH, 22
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 15
Arg Arg Glu Arg Asn Arg Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser
1
5
10
15
Arg Gly Lys Gly Arg Arg
20

What is claimed is:
1. A method for promoting the survival and/or function of
dopaminergic neurons, comprising administering to a subject in need thereof a pharmaceutically effective amount of
a composition comprising at least one of the following
peptides:
(a) a purified Amidated Dopamine Neuron Stimulating
peptide (ADNS peptide) comprising the amino acid
sequence ERNRQAAAANPENSRGK-amide (SEQ ID
NO: 2);
(b) a purified ADNS peptide comprising the amino acid
sequence FPLPA-amide (SEQ ID NO: 3); and
(c) a purified ADNS peptide comprising the amino acid
sequence PPEAPAEDRSL-amide (SEQ ID NO: 4)
wherein the composition is administered to a subject
having at least one condition selected from the group
consisting of Parkinson's Disease, Alzheimer's disease,
and Amyotrophic Lateral Sclerosis (ALS); and
wherein the composition is administered in an amount
sufficient to increase the level of at least one of dopamine and a dopamine metabolite in the subject.
2. The method of claim 1 wherein the composition
comprises a purified ADNS peptide comprising the amino
acid sequence PPEAPAEDRSL-amide (SEQ ID NO: 4).
3. A method for treating a brain disease or injury resulting
in dopaminergic deficiencies, comprising administering to a
subject in need thereof a pharmaceutically effective amount
of a composition comprising at least one of the following
peptides:
(a) a purified Amidated Dopamine Neuron Stimulating
peptide (ADNS peptide) comprising the amino acid
sequence ERNRQAAAANPENSRGK-amide (SEQ ID
NO: 2);
(b) a purified ADNS peptide comprising the amino acid
sequence FPLPA-amide (SEQ ID NO: 3); and
(c) a purified ADNS peptide comprising the amino acid
sequence PPEAPAEDRSL-amide (SEQ ID NO: 4);
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wherein said composition further comprises at least one of
a pharmaceutically acceptable vehicle, excipient, and
diluent,
wherein the brain disease or injury is at least one condition selected from the group consisting of Parkinson's
Disease, Alzheimer's disease, and Amyotrophic Lateral
Sclerosis (ALS); and
wherein the composition is administered in an amount
sufficient to increase the level of at least one of dopamine and a dopamine metabolite in the subject.
4. The method of claim 3 wherein the composition
comprises a purified ADNS peptide comprising the amino
acid sequence PPEAPAEDRSL-amide (SEQ ID NO: 4).
5. A method of increasing levels of at least one of
dopamine and a dopamine metabolite in a subject having
damaged dopamine neurons comprising
administering a pharmaceutically effective amount of a
composition comprising a purified peptide comprising
the amino acid sequence PPEAPAEDRSL-amide (SEQ
ID NO: 4) and at least one of a pharmaceutically
acceptable vehicle, excipient, and diluent,
wherein the damaged dopamine neurons are associated
with at least one condition selected from the group
consisting of Parkinson's Disease, Alzheimer's disease,
and Amyotrophic Lateral Sclerosis (ALS); and
wherein the composition is administered in an amount
sufficient to increase the level of at least one of dopamine and a dopamine metabolite in the subject.
6. The method of claim 1, wherein the level of at least one
of dopamine and a dopamine metabolite is measured by
microdialysis.
7. The method of claim 3, wherein the level of at least one
of dopamine and a dopamine metabolite is measured by
microdialysis.
8. The method of claim 5, wherein the level of at least one
of dopamine and a dopamine metabolite is measured by
microdialysis.
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